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Kaposi’s sarcoma-associated herpesvirus (KSHV) is the causative agent of Kaposi’s 
sarcoma (KS), primary effusion lymphoma (PEL), and KSHV-associated multicentric 
Castleman disease (KSHV-MCD) and KSHV-associated inflammatory cytokine syndrome 
(KICS). KICS is a newly described clinical entity associated with lytic reactivation and high-
level, systemic replication of KSHV. We characterized the clinical and laboratory features of 
a KICS patient over-time. Additionally, we compare the KICS patient to Kaposi’s sarcoma 
(KS) (n=11) and non-KS (n=6) cases. The KICS patient presented elevated levels of KSHV 
and IL-10, as expected. Treatment with tocilizumab effectively reduce his IL-10 level to 
undetectable. Surprisingly, this patient did not present high levels of IL-6.  We successfully 
sequenced the whole KSHV genome, which showed no differential mutation before KICS 
was officially diagnosed and after diagnosis. Phylogenetic analysis of the KICS consensus 
sequences showed that both sequences aligned to the K1 clade and were closely related to 
BAC16, JSC1 (cell line) and GK1B sequences. 
Additionally, KSHV-related malignancies have a highly active mTOR pathway, 
which makes mTOR a potential therapeutic target. Therefore, we sought to test MLN0128, 
an ATP-competitive inhibitor of mTOR, as treatment for PEL. Our results demonstrated that 
MLN0128 has a greater effect on inhibiting proliferation than allosteric mTOR inhibitor 
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rapamycin. MLN0128 has ~30 nM IC50 values across several PEL cell lines, including PEL 
that is resistant to conventional chemotherapy. MLN0128 induced apoptosis in PEL, whereas 
rapamycin only induced G1 arrest. MLN0128 inhibited phosphorylation of mTOR complex 1 
and 2 targets, while rapamycin only partially inhibited mTOR complex 1 targets. PEL 
xenograft mouse models treated with MLN0128 showed reduced effusion volumes in 
comparison to the vehicle group. Rapamycin resistant (RR) clones with an IC50 for 
rapamycin 10 times higher than the parental clones emerged consistently after rapamycin 
exposure as a result of transcriptional adaptation. MLN0128 was nevertheless capable of 
inducing apoptosis in these RR clones. Our results suggest that MLN0128 might offer a new 
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The mammalian target of rapamycin (mTOR) is an evolutionary-conserved 
kinase, with a central role in cell growth, survival, proliferation and metabolism 
(reviewed in (Guertin and Sabatini 2007)) (Figure 1). Importantly, the mTOR pathway is 
aberrantly activated in several malignancies, which makes mTOR a key target of 
chemotherapeutic drugs. mTOR functions in two structurally and functionally distinct 
complexes known as mTOR complex 1 (mTORC1) (Kim, Sarbassov et al. 2002) and 
mTOR complex 2 (mTORC2) (Jacinto, Loewith et al. 2004). All proteins of the mTOR 
pathway mentioned in this chapter are listed in Table 1. 
The mTORC1 contains the companion proteins, regulatory-associated protein of 
mTOR (raptor) and proline-rich AKT1 substrate 1 (PRAS40), which are unique to 
mTORC1 and mammalian lethal with SEC13 protein 8 (mLST8) found in both mTORC1 
and mTORC2. Raptor functions as a scaffold for recruiting mTORC1 substrates, such as 
eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1), and nutrient-
dependent enhancement of mTOR protein activity (Hara, Maruki et al. 2002, Kim, 
Sarbassov et al. 2002, Schalm, Fingar et al. 2003). PRAS40 is a negative regulator of 
mTOR; activated PRAS40 can bind mTOR via raptor and inhibit mTORC1 activity 
(Sancak, Thoreen et al. 2007). mLST8 enhances mTOR activity and is required for the 
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mTORC formation (Kakumoto, Ikeda et al. 2015). 
mTORC1 is a rapamycin and nutrient-sensitive multiprotein complex; its best-
known targets are p70 ribosomal S6 kinase 1 (S6K1) and 4EBP1. Phosphorylation of 
S6K1 at Thr389 by mTORC1 leads to the phosphorylation of 40S ribosomal protein S6 
(RPS6) thus stimulating protein synthesis (Magnuson, Ekim et al. 2012) (Figure 1). Also, 
mTORC1 phosphorylates 4EBP1 at multiple sites, causing its dissociation from 
eukaryotic translation initiation factor 4E (eIF4E), which allows the assembly of eIF4F 
complex (composed of eIF4E, eIF4G and eIF4A) and promotes cap-dependent mRNA 
translation (Hara, Maruki et al. 2002) (Figure 1). In high-nutrient conditions, the raptor-
mTOR interaction is stabilized, which promotes mTOR kinase activity and signals for an 
increase of protein synthesis and mRNA translation (Kim, Sarbassov et al. 2002). 
Additionally, mTORC1 is also involved in the regulating of autophagy. Under sufficient 
nutrient conditions, mTOR1 phosphorylates serine/threonine-protein kinase ULK1 (Ulk1) 
at Ser757, which prevents autophagy activation (Kim, Kundu et al. 2011) (Figure 1).  
On the other hand, mTORC2 is a rapamycin-resistant and nutrient insensitive 
complex, whose functions are not fully elucidated. mTORC2 also contains mLST8, but 
has the unique proteins rapamycin-insensitive companion of mTOR (rictor), mitogen-
activated protein kinase 2-associated protein 1 (mSIN1) and protein observed in rictor 
(PROTOR) (Jacinto, Loewith et al. 2004, Sarbassov, Ali et al. 2004, Frias, Thoreen et al. 
2006, Yang, Inoki et al. 2006, Pearce, Huang et al. 2007).  Rictor is the rapamycin-
insensitive component of mTORC2; both rictor and mSIN1 are required for mTORC2 
assembly and mTOR mediated activation of proteinase kinase B (Akt) (Sarbassov, Ali et 
al. 2004, Frias, Thoreen et al. 2006, Yang, Inoki et al. 2006). It has been shown that 
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PROTOR is unique to mTORC2 but it is not required for the complex assembly, however 
PROTOR functions are not fully elucidated (Pearce, Huang et al. 2007).  
mTORC2 best-known substrates are Akt and serine/threonine-protein kinase Sgk1 
(SGK1).  Akt phosphorylates a set of downstream targets and regulates several cellular 
processes, including the indirect activation of mTORC1 (reviewed in (Manning and 
Toker 2017). Akt is phosphorylated at Ser473 by mTORC2 and Thr308 by 3-
phosphoinositide-dependent protein kinase 1 (PDK1) (Alessi, Deak et al. 1997, Stokoe, 
Stephens et al. 1997, Stephens, Anderson et al. 1998, Sarbassov, Guertin et al. 2005) 
(Figure 1). Phosphorylation of both sites is required for full activation of Akt (Stokoe, 
Stephens et al. 1997). Akt can activate mTORC1 through a positive feedback loop 
mediated by tuberous sclerosis complex 2 (TSC2) (Sarbassov, Guertin et al. 2005, 
Guertin, Stevens et al. 2006).  TSC1 (hamarin) and TSC2 (tuberin) form a complex 
known as TSC. The TSC is a negative regulator for Rheb, a Ras-related small GTP 
binding protein (Rheb-GTP) (Garami, Zwartkruis et al. 2003). Rheb-GTP promotes the 
activation of mTORC1. Akt can phosphorylate TSC2 and block its activity, which results 
in the inactivation of Rheb-GAP and the accumulation of Rheb-GTP that promotes 
mTOR activity (Figure 1) (Inoki, Li et al. 2002, Tee, Manning et al. 2003). 
A more recently discovered target of mTORC2 is SGK1; both AKT and SGK1 
are members of the AGC family of protein kinases (Zhang, Cui et al. 2005, Tessier and 
Woodgett 2006, Garcia-Martinez and Alessi 2008). mTORC2 phosphorylates SGK1 at 
Ser422, in turn activated SGK1 phosphorylates N-myc downstream-regulated gene 1 
(NDRG1) (Murray, Campbell et al. 2004) (Figure 1). NDRG1 is involved in cellular 
growth and differentiation. Phosphorylation of Akt and SGK1/NDRG1 represents the 
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best-understood biomarker of mTORC2 activity. 
Upstream of mTOR, several components receive external signals, such as glucose 
and amino acid levels to regulate the signaling pathway. For example, activated 
phosphoinositide 3-kinase (P13K) phosphorylates phosphatidylinositol 3,4,5-diphosphate 
(PIP2) yielding phosphatidylinositol 3,4,5-triphosphate (PIP3) (Beitz, Fruman et al. 
1999). PIP3 recruits Akt to the plasma membrane, action required for Akt 
phosphorylation by PDK1 at Thr308 and by mTORC2 at Ser473 (Figure 1). Another 
important component upstream of mTOR is the aforementioned tuberous sclerosis 
complex (TSC). Genetic loss of TSC leads to increased proliferation and is hallmark of 
non-cancerous tumors (Gomez 1988). In sum, the mTOR pathway constitutes a 
convoluted network, which responds to outside stress factors that can impact the pathway 
at several points. 
Viruses are capable of exploiting mTOR’s fundamental role in cell machinery, by 
modulating stress factors to their advantage.  During viral infection, a possible cell 
response is to initiate autophagy in order to eliminate the invading pathogen or induce 
apoptosis to prevent further viral spread (reviewed in (Yordy and Iwasaki 2011, Nainu, 
Shiratsuchi et al. 2017)).  As mTOR activation promotes a cellular environment that is 
beneficial for viral growth and survival; viruses have developed different mechanisms to 
maintain basal activation of the mTOR pathway. Elucidating the interaction between 
viruses and mTOR is fundamental to develop improved treatments for cancer and viral 
infections targeting the mTOR pathway. Herpesviruses, in particular, have developed 
multiple means to target mTOR signaling. 
The human herpesvirus family includes Kaposi’s Sarcoma-associated herpesvirus 
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(KSHV/HHV8), Epstein-Barr virus (EBV/HHV4), human cytomegalovirus (hCMV 
/HHV5), human herpes virus (HHV6), human herpes virus (HHV7), and the alphas 
herpesviruses herpes simplex virus 1 (HSV1/HHV1), herpes simplex virus 
(HSV2/HHV2) and varicella zoster virus (VZV/HHV3). Both KSHV and EBV are 
known oncogenic viruses, causing Kaposi’s sarcoma (KS) and Burkitt’s lymphoma (BL) 
respectively. The following sections will provide an in depth analysis on the different 
strategies that KSHV, EBV and hCMV have evolved to hijack the mTOR pathway, plus a 
brief section discussing the role of mTOR in cancer and its treatment (Table 2). 
 
Kaposi’s Sarcoma-associated Herpesvirus (KSHV) 
KSHV is part of the gamma herpesvirus family and is an established oncovirus. 
KSHV is the causative agent of three malignancies: KS, primary effusion lymphoma 
(PEL) and KSHV-associated multicentric Castleman disease (KSHV-MCD) (Chang, 
Cesarman et al. 1994, Cesarman, Chang et al. 1995, Soulier, Grollet et al. 1995). 
Recently, KSHV has also been associated with an aggressive inflammatory syndrome, 
known Kaposi sarcoma inflammatory cytokine syndrome (KICS) (Uldrick, Wang et al. 
2010).  Like other herpesviruses, KSHV follows a dual life cycle: lytic and latent cycle. 
During KS and PEL, latency is established in most infected cells, with only a small 
fraction of cells in the lytic cycle. However, in both KSHV-MCD and KICS, KSHV 
infection follows cycles of viral reactivation required for pathogenesis.  
In general, KS is a highly angiogenic cancer, predominantly affecting spindle 
cells that express endothelial markers. KS main representation is as violaceous patches in 
the skin, but can also spread to the mouth, respiratory and gastrointestinal tract. KS is 
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normally treated with doxorubicin or paclitaxel in combination with HAART to control 
the HIV infection and usually has good prognosis (Bartnof 1997, Martin-Carbonero, 
Barrios et al. 2004, Cooley, Henry et al. 2007). On the other hand, PEL is an aggressive 
B-cell lymphoma usually characterized by effusions in body cavities, such as pleural, 
pericardial and peritoneal cavities. Currently PEL is treated with cyclophosphamide, 
doxorubicin, vincristine and prednisolone (CHOP) with a short median survival time of 
6.2 months (Boulanger, Gerard et al. 2005). KSHV-MCD also develops in B-cells and is 
characterized by flares of KSHV reactivation that induce inflammatory symptoms, 
sometimes called “B symptoms” (Oksenhendler, Duarte et al. 1996, Stebbing, 
Pantanowitz et al. 2008). B symptoms are defined as fevers, weight loss and night-
sweats.   KSHV-MCD is diagnosed by the identification of regressed germinal centers 
with a vascularized core and by a proliferation of polyclonal, IgM λ-restricted 
plasmacytoid cells in a lymph node biopsy (Oksenhendler, Duarte et al. 1996). KICS and 
KSHV-MCD share similar symptoms, which make its differential diagnosis complicated 
(Karass, Grossniklaus et al. 2017).  KICS is a novel disease with a very poor prognosis; 
several aspects of its pathogenesis and treatment are still unknown (Polizzotto, Uldrick et 
al. 2016). 
KSHV, as many other viruses, can modulate key cellular pathways to stimulate 
aberrant cell proliferation and survival (Moore and Chang 1998, Moore and Chang 1998, 
Ganem 2010). Overactivation of the mTOR pathway is often due to activating mutations 
upstream of mTOR and/or loss of tumor suppressors such as in the Phosphatase and 
Tensin homolog (PTEN) (Roy and Dittmer 2011). However in KSHV associated 
malignancies, no specific mutation has been detected and PTEN activity is intact. In fact, 
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experimental overexpression of PTEN in PEL leads to growth arrest (Roy and Dittmer 
2011). Several KSHV proteins are known to interact or mimic host proteins to maintain a 
constitutively active mTOR pathway, such as ORFK1 (K1) (Tomlinson and Damania 
2004), ORF74 (vGPCR) (Montaner, Sodhi et al. 2001, Sodhi, Chaisuparat et al. 2006), 
ORFK2 (vIL6) (Moore, Boshoff et al. 1996) and ORF45 (Kuang, Tang et al. 2008) 
whose interactions are summarized below (reviewed in (Bhatt and Damania 2012)). 
K1 is a 46-kDa transmembrane glycoprotein, encoded at the 5’ end of the KSHV 
genome. K1 is equivalent to latent membrane protein 1 (LMP-1) in EBV, based on its 
genomic position. K1 and the B-cell receptor (BCR) are structurally similar, as both 
contain a highly conserved immunoreceptor tyrosine-based activation motif (ITAM) 
capable of activating signaling pathways (Lee, Guo et al. 1998, Lagunoff, Majeti et al. 
1999).  However, K1 is constitutively active unlike BCR (Lagunoff, Majeti et al. 1999). 
Under normal conditions, the BCR complex can directly activate PI3K, which leads to 
the recruitment and activation of Akt. Interestingly, the constitutively active K1 can 
phosphorylate P13K, which leads to an aberrant activation of Akt (Lee, Guo et al. 1998, 
Tomlinson and Damania 2004). Akt activation is crucial, as it promotes cell survival 
mechanisms that are favorable for viral spread. PTEN is a negative regulator of the 
mTOR pathway, as it dephosphorylates PIP3, thus preventing Akt activation (Stambolic, 
Suzuki et al. 1998, Wu, Senechal et al. 1998). K1 is also capable of phosphorylating and 
consequently inactivating PTEN (Tomlinson and Damania 2004).  Therefore, K1 is 
capable of activating Akt by two different mechanisms.  
vGPCR/ORF74 is a seven-pass transmembrane protein, expressed during KSHV 
lytic replication.  vGPCR is homologous to cellular IL-8 chemokine receptor; however, 
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vGPCR is a ligand-independent receptor that remains constitutively active (Cesarman, 
Nador et al. 1996, Arvanitakis, Geras-Raaka et al. 1997, Rosenkilde, Kledal et al. 1999). 
vGPCR can activate PI3K, which triggers Akt translocation to the plasma membrane and 
its activation (Montaner, Sodhi et al. 2001, Martin, Galisteo et al. 2011). Overexpression 
of vGPCR phosphorylates TSC2, which promotes mTORC1 activation in a paracrine and 
autocrine approach (Sodhi, Chaisuparat et al. 2006). PI3K and TSC2 activation regulated 
by vGPCR are essential for KSHV tumorigenesis (Sodhi, Montaner et al. 2004, Sodhi, 
Chaisuparat et al. 2006, Montaner 2007).  
Viral IL-6 (vIL-6) is a homolog of the human IL-6 (hIL-6) cytokine (Moore, 
Boshoff et al. 1996). vIL-6 and hIL-6 are functionally identical, but structurally distinct. 
hIL-6 requires two IL-6 receptor subunits, IL-6Rα and gp130, for activating intracellular 
signaling. On the other hand, vIL-6 only requires gp130 for signaling, which circumvents 
the need of a second receptor and thus leading to uncontrolled signaling (Molden, Chang 
et al. 1997). Specifically, gp130 signaling can activate Akt via JAK2/PI3K 
phosphorylation (Morris, Punjabi et al. 2008). Additionally, activated JAK2 can also 
phosphorylate/activate STAT3, which increases the expression of gp130 through a 
positive feedback loop (O'Brien and Manolagas 1997). vIL-6 represents a KSHV-
mediated paracrine activation of the mTOR pathway. Of note, IL-6 is a key growth factor 
for KSHV-associated malignancies. IL-6 is an established autocrine growth factor for KS 
and is required for PEL growth and survival (Miles, Rezai et al. 1990, Asou, Said et al. 
1998). 
ORF45 is an immediate-early gene, which plays a critical role in the KSHV lytic 
replication cycle. ORF45 interacts with RSK1 and RSK2, both members of the p90 
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ribosomal S6 kinase (RSK) family. The ORF45-RSK complex stimulates, augments and 
maintains RSK kinase activity, which is required for the production of infectious viruses 
(Kuang, Tang et al. 2008, Kuang, Wu et al. 2009, Fu, Kuang et al. 2015). The aberrant 
activation of RSK leads to the phosphorylation of eukaryotic translation initiation factor 
4B (eIF4B) and RPS6, which initiates protein translation (Kuang, Fu et al. 2011). Under 
normal conditions, S6K1 (downstream of mTORC1) regulates eIF4B and S6 
phosphorylation (Figure 1). ORF45 thus represents a KSHV-mediated enhancement of 
protein translation that circumvents mTOR-signaling regulation during lytic replication. 
Epstein-Barr virus (EBV) 
EBV belongs to the gamma herpesvirus family and was the first human oncovirus 
discovered in 1964. Like KSHV, EBV infects B cells. EBV discovery was a key factor in 
elucidating the link between human cancer and viruses. However, EBV is best known as 
the causative agent of infectious mononucleosis. EBV is associated with a wide range of 
benign and malignant diseases, such as Burkitt's lymphoma (BL), Hodgkin's lymphoma 
(HL), nasopharyngeal carcinoma, gastric adenocarcinoma, hairy leukoplakia and others 
(Epstein, Achong et al. 1964, Levine, Ablashi et al. 1971, Reichart, Langford et al. 1989, 
Chen, Wen et al. 1993, Imai, Koizumi et al. 1994, Pathmanathan, Prasad et al. 1995). 
EBV is one of the most common infections in humans, with a serologic prevalence of 
about 95% (Cohen 2000). EBV infection is normally asymptomatic and life-long (Young 
and Rickinson 2004), however, EBV is also associated with about 200,000 cases of 
cancer per year (Parkin 2006). EBV can present both latent and lytic cycles, dependent on 
the cellular environment.  
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BL hallmark feature is the translocation between the MYC gene and one of the 
immunoglobulin heavy or light chain loci, which results in an aberrant expression of c-
myc (reviewed in (Allday 2009)). BL is a highly aggressive B-cell lymphoma with a 
short doubling time and high disease burden (reviewed in (Magrath 1990)) Currently 
three different types of BL have been described: endemic (eBL), sporadic (sBL) and 
HIV-associated BL. EBV is associated with more than 95% eBL cases, 30% of sBL cases 
and 25-40% of HIV-associated BL (Crawford 2001). Differential diagnosis is particularly 
complicated, due to BL’s similarities to diffuse large B-cell lymphoma, as both present c-
myc rearrangements. The specific immunophenotypic prototype of BL diagnosis is 
IgM+/CD10+/bcl-2–/bcl-6+ with the Ki-67 proliferation index nearly at 100% 
(Nakamura, Nakamine et al. 2002). Treatment is dependent on several factors, such 
patient age, BL type and disease stage, but usually comprises a dose-adjusted EPOCH 
treatment. There are still on-going clinical trials for other combination therapies in cases 
of relapsed or refractory disease, as they still have a poor prognosis (2019). Importantly, 
studies have shown the synergy between c-myc and PI3K deregulation in the 
lymphomagenesis of BL (Sander, Calado et al. 2012). Which evidence the dependence of 
most BL cases on an overactivated mTOR signaling. 
 HL is characterized by the disruption of the lymph node architecture and the 
presence of Hodgkin-Reed Sternberg cells (Drexler 1992). The role of EBV in HL is not 
fully elucidated, as it may play a direct or indirect role in cell transformation. HL are 
divided in 4 subtypes: lymphocyte predominance, nodular sclerosis, mixed cellularity, 
and lymphocyte depletion (Harris, Jaffe et al. 1994). Treatment and prognosis is 
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dependent on the patient’s age and gender, specific symptoms, cancer stage and HL type. 
HL is usually curable if treated on the early stages of disease (1980).  
EBV is another example of viral modulation of the mTOR pathway to stimulate 
cell proliferation and survival. Currently there is only one EBV protein that is associated 
with direct interaction with the mTOR pathway, the latent membrane protein 2A 
(LMP2A).  
LMP2A is a latent transmembrane protein, and its expression has been shown in 
several EBV associated malignancies (Scholle, Bendt et al. 2000). LMP2A has an ITAM, 
similarly to KSHV K1 protein, and its main role is to mimic an activated human BCR. 
Therefore, LMP2A can block normal B-cell signal transduction and induce EBV lytic 
replication (Longnecker and Miller 1996). LMP2A triggers constitutive Akt activation 
mediated by PI3K, which stimulates cell survival (Scholle, Bendt et al. 2000, Portis and 
Longnecker 2004, Moody, Scott et al. 2005). Importantly, recruitment of Syk and Lyn, 
tyrosine kinases, is required for LMP2A mediated activation of Akt (Swart, Ruf et al. 
2000). LMP2A modulation of the mTOR pathway has been shown in both lymphoma and 
carcinoma cells, demonstrating its importance in EBV-associated malignancies 
tumorigenesis (Portis and Longnecker 2004, Moody, Scott et al. 2005).  
 
Human Cytomegalovirus (hCMV) 
hCMV belongs to the beta herpesvirus family and its name is derived from its 
hallmark feature of enlarging infected cells (cytomegaly). hCMV infections in healthy 
individuals tend to be asymptomatic, but it establishes a life-long infection in 
hematopoietic stem cells (Sinclair 2008). The immune system is capable of controlling 
	 12	
hCMV cycles of reactivation. Only under circumstances of immunity suppression, such 
as HIV infection, pre-natal and post-natal infants or organ transplant, hCMV may cause 
serious disease (reviewed in (Mocarski 2007)).  Importantly, hCMV can be vertically 
transmitted through the uterus and breast-milk, and it’s the leading viral cause of birth 
defect with higher prevalence in developing countries (Kurath, Halwachs-Baumann et al. 
2010, Lanzieri, Dollard et al. 2014). Similarly to KSHV-induced KS and EBV-dependent 
B cells lymphomas of the CNS, uncontrolled hCMV infection is considered an AIDS-
defining illness, particularly in the eye and lungs.  
Currently, there are several drugs used as single agents or in combination 
therapies, to prevent hCMV infections in high-risk groups. CMV immunoglobulin G 
(CMV-IGIV) is FDA approved as preventive treatment for hCMV in solid organ 
transplant patients. CMV-IGIV can be used as a single therapy or in combination with 
anti-viral drugs (reviewed in (Nichols and Boeckh 2000). Ganciclovir is the most 
commonly used anti-viral drug for hCMV infection treatment (Mar, Cheng et al. 1983, 
Zaia, Baden et al. 2009, Gracia-Ahufinger, Gutierrez-Aroca et al. 2013). Later 
valganciclovir (Valcyte) was developed, which is a ganciclovir pro-drug with improved 
bioavailability and can be orally administered (Pescovitz, Rabkin et al. 2000). Due to 
resistance development, foscarnet and cidofovir may be used as a second-line antiviral 
therapy for ganciclovir-resistant and refractory hCMV infections (Minces, Nguyen et al. 
2014, Metafuni, Chiusolo et al. 2018).  However, the optimal second-line treatment is 
still debatable, as both foscarnet and cidofovir have a high risk of side effects and 
inconsistent results in the clinic (Asakura, Ikegame et al. 2010, Avery, Arav-Boger et al. 
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2016).  Recently, letermovir has entered the market as the first non-polymerase inhibitor 
for hCMV (Piret and Boivin 2019).  
hCMV is a slow replicating virus, which like KSHV and EVB requires 48 to 72 
hours to complete an infection cycle in culture. As the other members of the herpesvirus 
family, hCMV can increase host protein production, such as DNA replication enzymes 
and transcription factors necessary for viral replication, and also block antiviral responses 
to prevent premature cellular apoptosis (Huang 1975, Benson and Huang 1990, 
Yurochko, Hwang et al. 1997). Expectedly, hCMV has also evolved multiple 
mechanisms to maintain a constitutively active mTOR pathway, through proteins such as 
IEP72/IEP86 (Yu and Alwine 2002) and UL38 (Moorman, Cristea et al. 2008), co-
localization of mTORC1 and Rhes (Clippinger and Alwine 2012) and increase abundance 
of eIF4F complex (Walsh, Perez et al. 2005). 
IEP72 and IEP86 (also known as IE1 and IE2 respectively) are two major 
immediate early proteins that are highly expressed during hCMV lytic infection. IEP72 
and IEP86 have a variety of roles including transcriptional activators of cellular gene 
expression and are capable of autoregulating their own expression (Pizzorno, O'Hare et 
al. 1988, Liu, Hermiston et al. 1991, Colberg-Poley, Santomenna et al. 1992, Klucher, 
Sommer et al. 1993).  Importantly, they are required for hCMV early gene expression. 
Similarly to KSHV K1 and EBV LMP2A, CMV IEP72 and IEP86 can block apoptosis 
by inducing an aberrant Akt activation (Zhu, Shen et al. 1995, Yu and Alwine 2002). 
hCMV activation of Akt is also mediated by PI3K activation (Johnson, Wang et al. 
2001). Interestingly, hCMV induces a more potent activation of the mTOR-signaling 
pathway, when compared to normal growth factors (Peppenelli, Miller et al. 2018). A 
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direct comparison between KSHV, EBV and hCMV activation of mTOR signaling has 
not been conducted. 
UL38 is encoded within the UL37 intron and is highly conserved within the beta 
herpesvirus family (Terhune, Torigoi et al. 2007). UL38 has homologs in human 
herpesvirus 7 and 8 as well as in cytomegaloviruses from other primate and non-primate 
species, such chimpanzees, rhesus monkeys and mice (Rawlinson, Farrell et al. 1996, 
Davison, Dolan et al. 2003, Hansen, Strelow et al. 2003). UL38 is expressed during the 
early phase of infection and is required to maintain viability of host cells and thus 
efficient hCMV replication (Terhune, Torigoi et al. 2007). UL38 interacts and inhibits 
TSC2, which causes an aberrant activation of mTORC1 and blocks apoptosis (Moorman, 
Cristea et al. 2008). Interestingly, UL38 N-terminal 239 residues are sufficient to block 
apoptosis, but not for mTORC1 activation (Qian, Xuan et al. 2011). Therefore, UL38 
blockage of mTORC1 regulation may only represent one of the mechanisms through 
which UL38 blocks apoptosis.  
Furthermore, the binding motif of UL38 to TSC2 is not required for mTORC1 
activation (Bai, Xuan et al. 2015). Also, as mTOR1 is activated during early hCMV 
infection (potentially before UL38 is expressed), it hints to additional mechanisms to 
induce mTORC1 activation. Importantly, mTORC1 activation is maintained in hCMV-
infected cells even under oxidative stress and amino acid deprival, signals that should 
inhibit the mTOR signaling (Clippinger, Maguire et al. 2011, Tilton, Clippinger et al. 
2011). It has been recently shown that hCMV induces a dystein-dependent co-
localization of mTORC1 and Rhes, which induces mTORC1 activation (Clippinger and 
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Alwine 2012). This demonstrates the complexity of hCMV mechanisms to maintain 
mTORC1 activation. 
Due to mTORC1 aberrant activation by hCMV, 4EBP1 is phosphorylated and 
released from eIF4E during early infection. Additionally, hCMV is capable of increasing 
the abundance of eIF4E and eIF4G (eIF4F complex core components) and promoting the 
assembly of eIF4F (Walsh, Perez et al. 2005). This is another mechanism by which 
hCMV interacts with downstream component of the mTOR pathway and consequently 
increases mRNA cap translation. So, even though hCMV does not induce cell cycle 
progression and has no mitotic properties, it does activate the mTOR signaling to 
facilitate nutrient availability for the purpose of viral replication (Dittmer and Mocarski 
1997). Interestingly, other herperviruses, such as HSV, has the opposite effect and 
efficiently inhibit host protein synthesis (Walsh and Mohr 2004). This represents 
different viral strategies to modulate the host environment to increase viral replication. 
 
mTOR in cancer 
Several types of cancer have an overactivated mTOR pathway, which supports the 
uncontrolled growth of malignant cells (Populo, Lopes et al. 2012). Deregulation of the 
mTOR pathway in cancer has been reported due to PI3K amplification or mutation, 
PTEN loss of function, AKT overexpression, and S6K1, 4EBP1 and eIF4E 
overexpression (Populo, Lopes et al. 2012).  
Over the years, the mTOR pathway has been the target of chemotherapeutic 
research.  Rapamycin, previously known as sirolimus, is a well-studied mTOR allosteric 
inhibitor that was initially isolated from the bacterium Streptomyces hygroscopicus. Due 
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to its anti-proliferative activity on cancer, several rapalogs (rapamycin analogs) were 
developed with improved pharmacokinetics and solubility. Rapamycin and its rapalogs, 
form a complex with FKBP12, the complex binds mTOR at its FKBP12-rapamycin 
binding domain (Banaszynski, Liu et al. 2005). It has been established that rapamycin can 
only target mTORC1, and furthermore only inhibit mTORC1 activity on certain 
substrates, such as S6K1 but not on 4EBP1 in certain malignancies (Choo, Yoon et al. 
2008, Feldman, Apsel et al. 2009, Thoreen and Sabatini 2009, Yoon and Roux 2013). 
Since rapamycin does not target mTORC2, this may result in a compensatory activation 
of Akt and subsequent mTORC1 activation (O'Reilly, Rojo et al. 2006). 
Rapamycin has been extensively studied in preclinical and clinical studies. 
Rapamycin effectively inhibit proliferation and arrest cells G1/G0 phase of PEL and 
Burkitt’s lymphoma (Sin, Roy et al. 2007, Zhou, Zhu et al. 2017). However, as it does 
not induce apoptosis, resistance readily develops which limits its clinical efficacy 
(Gasperini and Tosato 2009). Currently, rapamycin is only FDA-approved as treatment 
for organ transplant patients to prevent rejection (Augustine, Bodziak et al. 2007). 
Temsirolimus (rapalog) is approved for the treatment of advanced renal cell carcinoma 
(Kwitkowski, Prowell et al. 2010) 
The partial inhibition of rapamycin let to the development of novel techniques to 
inhibit the mTOR pathway. For example BEZ-235 is a dual inhibitor of PDK1 (upstream 
of mTOR) and mTOR. BEZ-235 had promising results in vitro and in vivo, but showed 
high toxicity in the clinic that resulted in no further development of this drug (Maira, 
Stauffer et al. 2008, Carlo, Molina et al. 2016, Fazio, Buzzoni et al. 2016, Seront, Rottey 
et al. 2016).  
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Additionally, there are second-generation mTOR inhibitors, known as ATP-
competitive inhibitors capable of targeting both mTORC1 and mTORC2 (Liu, Kang et al. 
2012).  For example, MLN0128 (INK128, sapanisertib) has been extensively studied in 
pre-clinical studies on different malignancies (Janes, Vu et al. 2013, Ingels, Zhao et al. 
2014, Kannan, Lin et al. 2016, Zeng, Wang et al. 2016). MLN0128 has high effectiveness 
and prevent resistance formation due to its high selectivity for mTOR, induction of 
apoptosis and low toxicity. Importantly, MLN0128 was effective against doxorubin-
resistant PEL and rapamycin-resistant PEL (Caro-Vegas, Bailey et al. 2019). Currently, 
MLN0128 has passed phase 1 clinical trials and is undergoing phase 2 for relapsed 
lymphoma and metastatic renal carcinoma (Ghobrial, Siegel et al. 2016, 2019, 2019). 
 Recently, a third-generation mTOR inhibitor was constructed by combining 
rapamycin and MLN0128 through a linker, RapaLink-1. The combination of both drugs 
prevented resistance observed with single drug therapy (Rodrik-Outmezguine, Okaniwa 
et al. 2016). All the different mTOR inhibitors have proven potential as a 
chemotherapeutic target, however the differential effect on each type of cancer needs to 
be further studied (Dittmer, Bhatt et al. 2012). 
 
Conclusions 
Viruses are completely dependent on the host cell machinery to replicate and 
spread infection. Consequently, viruses have developed complex mechanisms to hijack 
the cell machinery for their own use. The two main strategies are to increase nutrient 
availability and prevent cell death. In this way, there are more components available for 
viral progeny production. 
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The mTOR pathway is a convoluted signaling network and is the central regulator 
of cell metabolism, growth, proliferation and survival. The mTOR pathway integrates 
both extracellular signals, such as glucose and amino acid levels, and intracellular signals 
to maintain cellular homeostasis. mTOR is found in 2 main complexes, mTORC1 and 
mTORC2, each one with their own set of downstream targets that control specific cellular 
mechanisms (Figure 1). Importantly, the mTOR pathway is aberrantly activated in 
several types of malignancies, which leads to the uncontrolled growth and survival of 
malignant cells. 
Herpesviruses are a family of large DNA viruses, which are incredibly 
widespread among the human population, some of them having up to 90% of prevalence. 
Particularly, herpesviruses establish a latent infection, with cycles of viral reactivation to 
maintain and spread infection. The cycles of reactivation are normally asymptomatic, 
however in some rare scenarios, such as KICS, reactivation is fatal for the patient. 
Importantly, the herpesvirus family, which include two main oncoviruses, are master 
regulators of the mTOR pathway. By modulating the mTOR pathway, herpesviruses are 
not only capable of maintaining latency, but in the long run also develop malignancies. 
Some of the mechanisms are shared among herpesviruses, while others have 
opposite effects. For example, all of the viruses described in this chapter have a viral 
protein to aberrantly activate the mTOR pathway by targeting the upstream component 
PI3K and Akt. Specifically, both KSHV K1 (Tomlinson and Damania 2004) and EBV 
LMP2A (Scholle, Bendt et al. 2000) mimic an overactive BCR, while hCMV IEP72/IE86 
(Yu and Alwine 2002) activates Akt through an unknown mechanism. Other strategies 
involve the modulation of downstream targets of mTOR, such as KSHV ORF45 that 
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leads to S6 activation (Kuang, Tang et al. 2008), or hCMV that leads to the upregulation 
of eIEF4F complex formation and therefore an increase in protein synthesis (Walsh, 
Perez et al. 2005). Interestingly, HSV has an opposite mechanism, which generates the 
downregulation of protein synthesis (Walsh and Mohr 2004). For sake of time, we do not 
delve into the fascinating molecular details that connect HSV to mTOR signaling, 
reviewed in (Le Sage, Cinti et al. 2016). 
In this chapter we described the different herpesvirus (KSHV, EBV and hCMV) 
mechanisms to modulate the mTOR pathway. It is important to study the relationship 
between viruses and the mTOR pathway as it may provide key information to produce 
more efficient anti-viral drugs. Additionally, mTOR is a central component of cancer 
treatment, as several drugs such as rapamycin, MLN018 and others are FDA approved or 
in clinical studies for different malignancies. Therefore, further knowledge on how 
viruses modulate mTOR, may give insights into next-generation drugs or combination 
therapies using anti-viral drugs and mTOR inhibitors. 
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Table I. 1: mTOR signaling proteins information 
 
  
Protein Name Protein 
Short Name
Gene Name Uniprot 
Code
3-phosphoinositide-dependent protein kinase 1 PDK1 PDPK1 O15530
40S ribosomal protein S6 RPS6 RPS6 P62753
70 kDa ribosomal protein S6 kinase 1 S6K1 RPS6KB1 P23443
Eukaryotic initiation factor 4A-I eIF4A EIF4A1 P60842
Eukaryotic translation initiation factor 4 gamma 1 eIF4G EIF4G1 Q04637
Eukaryotic translation initiation factor 4E eIF4E EIF4E P06730
Eukaryotic translation initiation factor 4E-binding protein 1 4EBP1 EIF4EBP1 Q13541
Hamartin TSC1 TSC1 Q92574
Mammalian lethal with SEC13 protein 8 mLST8 MLST8 Q9BVC4
Mammalian target of rapamycin mTOR MTOR P42345
Mitogen-activated protein kinase 2-associated protein 1 mSIN1 MAPKAP1 Q9BPZ7
N-myc downstream-regulated gene 1 protein NDRG1 NDRG1 Q92597
Peptidyl-prolyl cis-trans isomerase FKBP1A FKBP1 FKBP1A P62942
Phosphatase and tensin homolog PTEN PTEN P60484
Phosphoinositide 3-kinase PI3K PIK3CA P42336
Proline-rich AKT1 substrate 1 PRAS40 AKT1S1 Q96B36
Protein kinase B AKT/PKB AKT1 P31749
Protein observed with Rictor-1 Protor-1 PRR5 P85299
Rapamycin-insensitive companion of mTOR Rictor RICTOR Q6R327
Ras-related small GTP binding protein Rheb RHEB Q15382
Regulatory-associated protein of mTOR Raptor RPTOR Q8N122
Serine/threonine-protein kinase Sgk1 SGK1 SGK1 O00141
Serine/threonine-protein kinase ULK1 Ulk1 ULK1 O75385
Tuberin TSC2 TSC2 P49815
	 21	
Table I. 2: Herpesviruses that target the mTOR pathway 
 
  
Virus Viral Protein Target
KSHV K1 PI3K/Akt activation and PTEN inactivation
KSHV vGPCR PI3K/Akt activation
KSHV vIL-6 Akt activation
KSHV ORF45 RSK/eIF4B and S6 activation
EBV LMP2A PI3K/Akt activation
hCMV IEP72/IEP86 PI3K/Akt activation
hCMV UL38 TSC2 inhibiion/mTORC1 activation
hCMV - mTORC1 and Rhes co-localization / mTORC1 activation
hCMV - Upregulation of eIEF4F formation
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Table I. 3: Drugs and their specific targets 
    
Drug Target
BEZ-235 PI3K/mTOR inhibitor
Cyclophosphamide Nitrogen mustard alkylating agent






Vincristine Polymerization of microtubules inhibitor
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CHAPTER II: KSHV-ASSOCIATED INFLAMMATORY CYTOKINE 




Kaposi Sarcoma associated herpesvirus (KSHV), also known as human 
herpesvirus-8, is the etiologic agent of Kaposi sarcoma (KS), primary effusion lymphoma 
(PEL), and the plasmablastic variant of multicentric Castleman disease (KSHV-MCD) 
(reviewed in (Dittmer and Damania 2016)). Interestingly, primary KSHV infections are 
largely asymptomatic. KSHV-associated malignancies often occur in human 
immunodeficiency virus (HIV)-positive patients. Globally, KS is the single most 
common cancer in people living with HIV today. KS predominantly develops in spindle 
cells, with a unique clinical manifestation of violaceous lesions in the skin and the 
respiratory and gastrointestinal tract. On the other hand, PEL and KSHV-MCD are B-cell 
lymphoproliferative disorders. In KS and PEL, KSHV establishes a latent infection in 
most infected cells. KSHV-MCD is associated with viral lytic reactivation in a proportion 
of KSHV-infected cells (Oksenhendler, Duarte et al. 1996). Even in KSHV-MCD 
systemic viral loads seldom exceed 104 copies / ml (Tamburro et al. 2012). By contrast, 
KSHV-associated inflammatory cytokine syndrome (KICS) is a newly described clinical 
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entity associated with lytic reactivation and high-levels of systemic replication of KSHV 
(Uldrick, Wang et al. 2010). 
The main clinical manifestations of KSHV-MCD are lymphadenopathy, 
splenomegaly and inflammatory symptoms, including fatigue, fever and cachexia. 
Anemia, thrombocytopenia, hypoalbuminemia, hyponatremia are common laboratory 
abnormalities (Polizzotto, Uldrick et al. 2012). The symptoms are thought to be 
secondary to systemically elevated levels of viral and human interleukin 6 (vIL-6 and 
hIL-6) and human interleukin 10 (hIL-10) resulting from KSHV reactivation (Brandt, 
Bodine et al. 1990, Oksenhendler, Carcelain et al. 2000, Uldrick, Wang et al. 2010).  
In addition to these specific symptoms, KICS patients also have a higher KSHV-
associated malignancy burden (KS and PEL) and an elevated risk of death compared to 
KS, PEL or KSHV-MCD alone (Polizzotto, Uldrick et al. 2016). Of note, KICS can 
develop despite control of HIV viremia (Cantos, Kalapila et al. 2017) and KSHV 
replicates to exceedingly systemic high levels (Tamburro, Yang et al. 2012). Thus, KICS 
is not just a manifestation of end-stage Acquired immune deficiency syndrome (AIDS), 
rather HIV replication and KSHV replication can be uncoupled.   
As KICS and KSHV-MCD share a similar clinical representation and cytokine 
signature, KSHV-MCD must be ruled out by pathologic evaluation before KICS can be 
diagnosed (Karass, Grossniklaus et al. 2017). Currently, KICS has no established 
treatment; therefore, similar treatment strategies to KSHV-MCD have been suggested, 
such as rituximab and liposomal doxorubixin (Uldrick, Polizzotto et al. 2014) or high-
dose zidovudine and valganciclovir (Uldrick, Polizzotto et al. 2011). It has also been 
suggested that KS becomes resistant to therapy in KICS patients, due to high levels of 
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cytokine release that promotes an abnormal cell proliferation, which makes treating KICS 
patients challenging (Uldrick, Wang et al. 2010).  
Here, we describe one KICS case patient treated at the University of North 
Carolina at Chapel Hill Hospital. We compare clinical and laboratory conditions of the 
KICS patient with a group of eleven KS and HIV infected patients and six non-KS and 
HIV infected patients. The comparison allowed us to further elucidate the pathogenesis of 
KICS in the context of other KSHV malignancies and suggests IL-10 as a potential 
biomarker to follow disease progression. Also, using genome-wide overlapping PCR 
(AmpliSeq), we obtained the complete KSHV sequence by next-generation sequencing 
from two different time points of the disease. These represent one of the few KSHV 
sequences from circulating rather than tumor-associated KSHV genomes.  
 
Methods 
Plasma isolation. 20 mL of whole blood was collected in purple cap EDTA tubes. 
Samples were centrifuged two times at 400g for 10 minutes. Plasma was stored in 1 mL 
aliquots in matrix tubes (Matrix Technologies Corp. #4252) at -80ºC. 
DNA extraction.  DNA was extracted using a Roche MagNA Pure Compact Instrument 
(Roche, #03731146001) and nucleic acid isolation kit i-large volume (Roche, 
#03730972001). 10 µL of a control plasmid, Fly 2.0 (Addgene #117418), was added to 
each sample to serve as control for DNA extraction efficiency.  
Viral load assay. Following DNA extraction qPCR was performed on the samples using 
a 3-primer master mix assay. Primers were designed for KSHV, EBV, and FLY 2.0 and 
obtained from Europhins Genomics. KSHV: LANA78-F (Jacobson) 
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GGAAGAGCCCATAATCTTGC and LANA78(2)-R (Jacobson) 
GCCTCATACGAACTCCAGGT. EBV: EBNA3C-F (Hilscher, Jacobson) 
AAGGTGCATTTACCCCACTG and EBNA3C-R (Hilscher, Jacobson) 
AGCAGTAGCTTGGGAACACC. Fly: Flyflap-f (Plaskon, Afronia) 
AATCATAAAGCGTTTTAAGCTCCAACGA and Fly Flyflap-r (Plaskon, Afronia) 
AATCATAATTCCTGACTCCCAAGTGGAC. Individual master mixes (40 reactions) 
for each primer were made by adding 20 µL of 5 µM of primer pair to 400 µL of SYBR® 
Select Master Mix (ThermoFisher/ABI, # 4472920). 9 µL of DNA sample and 9.9 ul of 
master mix were used for each well (125 nM final concentration). For each primer pair, 
we generated an oligonucleotide to serve as a template for creating a copy number 
standard curve. The oligonucleotide standards (Eurofin Genomics) were diluted to 
construct standard curves with a starting concentration of 100,000 copies/µL.  Reactions 
were set up using a Freedom Evo 150 robot (Tecan Group Ltd.) in LightCycler® 480 
Multiwell 384 Plates (Roche Catalog # 04729749001). PCR reactions were carried out 
and read with a LightCycler® 480 II/384 (Roche) instrument. Cycle conditions were 
95°C: 5 min, (95°C: 15 sec, 62°C: 1 min, x40).  
ELISA. IL-6, IL-8 and IL-10 were quantify using ready-set-go kit (eBioscience) per 
manufacturer instructions. Plates were washed with plate washer ELx405 (Biotek). 
Absorbance was measured at 450 nm using spectrophotometer Infinite M200 PRO 
(Tecan).  
Luminex assay and analysis. Plasma was tested with a human cytokine magnetic 35-
plex panel (Life Technologies) per the manufacturer’s instructions and analyzed with a 
MAGPIX instrument (Luminex). R version 3.5.1 was used to conduct analysis and 
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generate figures. Data was scaled and subjected to principle component analysis (PCA) 
The code is available at: https://bitbucket.org/dittmerlab/r_methods_cytokine/src/master/ 
Viral sequencing and mutation calling analysis.  Total nucleic acid was extracted from 
1 mL of plasma as described above and quantitated by Qubit 3.0 dsDNA HS Assay (Life 
Technologies). Custom Ion Ampliseq primer pools (Life Technologies) were design to 
amplify the viral genome using KSHV BAC16 (JSC-1 strain, GQ994935) as target (see 
supplemental data for bed files). Libraries were prepared from 100 ng DNA with Ion 
AmpliSeq Exome RDY Library Preparation Kit (Life Technologies) using protocol 
MAN00009808 Rev: A.0. Libraries were quantitated by Qubit dsDNA HS Assay, sized 
with Agilent Bioanalyzer 2100 High Sensitivity DNA Assay (Agilent Technologies), and 
pooled to 80 pM final concentration. Templating and loading onto the Ion 540 Chip (Life 
Technologies) were automated on the Ion Chef (Life Technologies). Samples were 
sequenced on the Ion S5 System (Life Technologies). Base calling was performed on the 
Ion S5 (Life Technologies) with default parameters. Subsequent steps included quality 
filtering and trimming using bbduk version 37.25 (https://jgi.doe.gov/data-and-
tools/bbtools/) (k=23 mink=11 ktrim=r hdist=1 minlength=50 qtrim=rl trimq=20 ftl=10 
ftr=600 maq=20 tpe tbo). Trimmed reads were mapped to the KSHV genome (NC 
009333) using CLC Genomics Workbench 9 (CLC bio). First, variants were detected 
using the CLC basic variant detection tool. Only variants that were non-synonymous, 
minimum average quality score > 19, minimum frequency > 90%, minimum coverage > 
40 and forward and reverse balance > 0.05 are reported. Second, reads were error 
corrected and normalized using BBmap. Next, sequences were aligned to NC009333 
modified with annotation SOURCE = "NotCoveredByUNCAmpliSeq" to indicate 
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regions of the genome that were not included in the UNC-designed KSHV AmplISeq 
PCR array using Genious mapper. Multiple best matches were mapped randomly and a 
consensus built based on majority calls at a minimum read coverage of N = 5.  Thereafter 
the consensus was inspected and poly-nucleotide runs corrected to restore full-length 
orfs. In a second step, the error-corrected reads were remapped against these consensus 
sequences and the final consensuses at 1x coverage were obtained. Gaps were repaired 
from the target to restore open reading frames (annotated). In-frame Indels and SNV were 
maintained. 
Phylogenetic Tree analysis. To compare our KSHV isolate to existing whole genome 
data, we used Geneious and the following sequences obtained from Genbank: NC009333, 
LC200589, LC200588, LC200587, LC200586, AP017458, U93872, KT271468, 
KT271467, KT271466, KT271465, KT271464, KT271463, KT271462, KT271461, 
KT271460, KT271459, KT271458, KT271457, KT271456, KT271455, KT271454, 
KT271453, GQ994935, KF588566, JQ619843, JX228174, HQ404500 and AF148805. 
KICS patient sequence is indicated as consensus09 and consensus10. 
Statistics. Results are reported as mean ± SD. All cellular experiments were repeated in 
at least three complete biological replicates. Unpaired 2-tailed t-test with Welch 
correction (not assuming equal variance) was used to compare groups.  
Study approval. Studies were approval by IRB of the University of North Carolina, 





KICS case clinical presentation 
The patient was a 45-year old male with HIV, who had initiated treatment with an 
integrase inhibitor-based antiretroviral regimen when he presented with dyspnea, fevers 
and violaceous skin lesions.  Skin biopsy confirmed KS.  He was admitted one month 
later with disease progression and at that time, a computed tomography scan of the chest 
demonstrated lung lesions thought to be pulmonary KS. The patient had recurrent 
episodes of fever and pancytopenia. As repeated infectious evaluations were negative, 
these signs were thought to be secondary to KS - immune reconstitution syndrome (KS-
IRIS). After initiating treatment with doxorubicin, he had clinical improvement. Eight 
months later, his KS progressed and required a change in treatment to paclitaxel. The 
patient was readmitted with shortness of breath, fatigue, pancytopenia and fevers. He 
underwent a bronchoscopy with transbronchial biopsies confirming pulmonary KS 
(Figure 1). KS biopsy was positive for LANA stain. At eight months after initiating HIV 
therapy, he was believed to have KICS rather than IRIS and treated with tocilizumab, a 
humanized monoclonal antibody against the interleukin-6 receptor (IL-6R) that is 
approved for classic Castleman’s disease, with good initial response. However, his health 
continued to decline despite the addition of rituximab to his treatment regimen.  
Blood samples from four different time points were available for analysis: (A) 
Day 0, Patient was diagnosed with KS, (B) day 30, Patient was diagnosed with KICS and 
had received first dose of tocilizumab 23 days earlier, (C) day 30, one hour after patient 
received a second dose of tocilizumab and (D) day 36, i.e. six days after patient was 
treated with tocilizumab. We compared the laboratory data of the KICS patient to 11 
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KS/HIV-positive and 6 non-KS/HIV-positive cancer patients.  All patients were male 
ranging from 28 to 59 years. In the non-KS group, we included 2 cases with B-cell 
lymphoma, 2 diffuse large B-cell lymphoma and 2 Hodgkin’s lymphoma, each. 
 
KICS patient had high levels of KSHV in plasma, but HIV remained undetectable 
At time point A, the patient had a KSHV viral load (total DNA) of 2.4 *106 
copies/mL, which decreased to 6.7*105 copies/mL after single dose tocilizumab (time 
point D). The KS group and non-KS group had an average of 280 copies/mL and 40 
copies/mL of plasma KSHV respectively, i.e. about a 3-log lower than the lowest KICS 
value (Figure 2A). The KICS patient had an undetectable HIV viral load at timepoints 
(A) and (D), while HIV viral load for the KS group ranged from undetectable to 5.2*103 
copies/mL and the non-KS group ranged from undetectable to 5.0*104 copies per mL 
(Figure 2B). Thus, this case uncouples high-level KSHV replication from high-level HIV 
replication. 
 
KICS could be differentiated from KS by its cytokine profile 
To test the hypothesis that cytokine levels correlate with KICS and can be used to 
follow treatment, we measured (i) IL-6, IL-10 and IL-8 by ELISA and (ii) a panel of 34 
cytokines by Luminex in KICS patient (n=1, 4 timepoints=A, B, C, and D), KS positive 
(n=12), and KS -negative (n=6) cancer patients with HIV. Historically, high levels of IL-
6 are associated with KICS; however, this patient did not exhibit significant levels of IL-
6 at time of KICS diagnosis (A. undetectable, B. 22 pg/mL). IL-6 reactivity in ELISA 
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increased 10-fold upon treatment with tocilizumab: to 324 pg/mL at 23 days after dose 
1(C), and 222 pg/mL at 6 days after dose 2 (D) (Figure 2C).  
IL-10 increased 3-fold after the patient was clinically diagnosed with KICS to 331 
pg/mL (B), compared to KS (130 pg/mL (A), remained level after a single dose of 
tocilizumab (C) followed by a drastic decrease at day 6 after the second tocilizumab 
treatment (Figure 2D). The KICS patient did not show substantial IL-8 levels in any of 
the timepoints (Figure 2E). None of the patients in KS and non-KS groups presented 
elevated values of any of the three cytokines (Figure 2C-E), confirming IL-6 and IL-10 
are closely associated with KICS. 
Luminex-based multiplex analysis was used to study a broader range of cytokines. 
Principal component analysis identified IL-6 and IL-10 as the main cytokines driving the 
difference between KS and KICS and between fulminant KICS (PC1). TNF and IL-9, 
pro-inflammatory cytokines were the main drivers of PC2 (Figure 2F), which represent 
differences between individuals and between KS and non-KS. Together PC1 and PC2 
explained 69.2% of the variation in this group. These experiments show that was possible 
to differentiate KICS from KS by cytokine profiling as disease progressed clinically away 
from KS in timepoints B, C and D (Figure 2G), and that perhaps measuring IL-10 in 
addition to IL-6 may have a role in monitoring KICS progression.  
 
KSHV genomes isolated from KICS patient. 
We used PCR-based enrichment (AmpliSeq) and Ion Torrent chemistry to 
determine the complete genome sequence of KSHV in this patient. We obtained high 
confidence whole genome sequences for timepoints A and B, as KSHV viral loads were 
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high enough (≥105 copies/ml) to yield high quality viral DNA after enrichment. In total 
1,381,470 raw reads for A and 3,769,841 sequences for B mapped to the KSHV reference 
sequence (Genbank ID: NC_009333) (Figure 3A). With the exception of six regions this 
primer set covered each position of the genome with overlapping PCR products. We did 
not find any INDELs that were present in sample A and not sample B or vice versa. 
Therefore, we do not think that a spontaneous mutation in the KSHV genome was 
responsible for high replicative phenotype of KICS.  
Whether any of the sequence differences seen in this patient KSHV genomes as 
compared to the KSHV reference sequence, which is based on AIDS-KS cases and the 
BC-1 PEL genome (Russo, Bohenzky et al. 1996) have functional consequences for 
KSHV replication in culture is the subject of future studies. Based on a comparison of 29 
full length KSHV genome sequences this isolate aligned to the Western-AIDS PEL and 
KS derived sequences. To identify the K1 clade that this KSHV isolate belongs to, we 
used Geneious. Both sequences align with clade A, shown in blue (Figure 3B). In sum, 
KICS represent a rare and much needed scientific opportunity to obtain complete KSHV 
genome information, pertaining to viral strains of demonstrated in vivo replication 
potential and human infectivity. At the same time, no single case study or limited case 
series can identify tell-tale genomic alterations that would revolutionize our 
understanding of KSHV replication. 
 
Discussion 
KICS represent the most aggressive and clinically fatal outcome of KSHV 
reactivation disease. KICS is convincingly associated with high-level KSHV replication 
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and a systemic cytokine storm dominated by IL-6 and IL-10 (Polizzotto, Uldrick et al. 
2016). Very likely these cytokines are the mechanistic driver of the clinical disease 
phenotype and may constitute a target for intervention. Due to the clinical similarities 
between KICS and KSHV-MCD, treatments with efficacy in KSHV-MCD may also have 
efficacy in KICS, though the accelerated clinical course of KICS requires more 
aggressive interventions. Further studies are urgently needed to understand the biology of 
KICS, to differentiate KICS from KSHV-MCD or KS-IRIS.  
This KICS patient did not initially present with vastly elevated levels of IL-6, 
instead the most prominent disease marker was IL-10 (and KSHV viral load). KSHV 
copy number decreased after treatment with tocilizumab. Tocilizumab reduced IL-10 
levels, whereas IL-6 dramatically increased after treatment was initiated. Because 
tocilizumab is an IL-6 receptor inhibitor, it may have interfered with the IL-6 ELISA or I 
may be that IL-6, even though present at high levels, had no biological activity on IL6 
receptor signaling. Only a bioassay for IL6 activity could distinguish among these 
possibilities. As with all case studies, while these correlations represent logical, 
biologically plausible, and tempting rationales for clinical treatment opportunities formal 
clinical trials are needed to evaluate these conjectures. 
We successfully sequenced a second KSHV genome from patient plasma. Pre-
NGS enrichment represents an efficient method to only sequence the virus in the 
background of a high concentration of contaminating human DNA in the sample. It did 
little, however, to overcome the dependence on high KSHV genome copy number in 
order to obtain robust, reliable and reproducible sequence data. Whereas complete single 
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genome sequencing has become possible for HIV (Berg, Yamaguchi et al. 2016) it 
remains an elusive target for the large herpesviruses and a gap in our research toolset.   
There are limitations to the sequence information gathered from this study, many 
of which are inherent to targeted NGS. First, we were unable to design capture primers to 
six regions of the KSHV genome (GQ994935): 24,213-25,057 (845 bp), 113949-114,092 
(144 bp), 117,733-118,873 (1,141 bp), 120,140-120,301 (162bp), 124,968-126,099 
(1,132bp), and 137,588-137,917 (330 bp). Here, the sequence from the target genome 
was inserted. The bed files for each amplicon are provided in supplemental data. Second, 
even though we were able to design primers against the remainder of the genome, not all 
amplicons amplified their target. This resulted in artificial deletions that were repaired 
from the target genome as annotated. Third, short-read sequencing was unable to 
correctly resolve the viral repeat regions. Hence, the number of repeats reported is likely 
an underestimation of the true number of repeats. Only sub-cloning and 3rd generation 
NGS, such as Oxford's Minion technology would be able to resolve the internal repeats in 
KSHV. Only sequencing of the circular episome using 3 rd generation NGS or manual 
sequencing as illustrated in (Lagunoff and Ganem 1997) would be able to correctly 
resolve the terminal repeats. Fourth, there are NGS chemistry related errors, such as 
undercounting of polynucleotide repeats. These were corrected from the target sequence. 
Forth, to maximize capture and recovery total DNA in plasma was used as input, rather 
than purified virion DNA. This includes DNA from infectious particles but also DNA 
released from dying tumor cells or cell that disintegrated due to viral replication. We do 
not know the relative contribution of either to the final sequence. In the end, only high 
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confidence polymorphisms were called using the standards established for human clinical 
mutation calling. 
It is conceivable that a specific mutation in the KSHV genome is associated with 
a high replicative phenotype during KICS. We were not able to identify a significant 
SNV that differed from consensus A (before KICS was diagnosed) and consensus B 
(after KICS was officially diagnosed). As expected, the virus had low genetic variation 
over time and compared to the reference genome, with the exception of the variable 
regions in K1.  
The patient presented in this study was HIV seropositive, but at the time of KICS 
had no detectable HIV viral load. This was unexpected if one considers KSHV-associated 
malignancies only in the context of late-state age, as during the 1990 epidemic in US and 
European MSM (1981). KS has since become appreciated as a much more varied disease 
entity. Particularly in KSHV endemic regions is often independent of HIV viral load and 
CD4 counts (Hosseinipour, Sweet et al. 2014). In the same setting, IL6 and IL10 are 
often elevated in pediatric KS with lymph node involvement and KSHV-MCD is seen 
more frequent than previously assumed, reinforcing the connection between KSHV 
replication and KSHV-induced pathology in the lymphoid compartment (Gopal, Liomba 






Figure II. 1: Clinical manifestation of patient with KICS 
(A) PET-CT scans demonstrated hypermetabolic lymph nodes in chest, and the 
(B) CT images taken in the same visit demonstrated presence of pulmonary KS. 
Histopathology of transbrochial biopsies showed (C) cancerous arrangement by H&E 




Figure II. 2: Systemic viral and cytokine elevation present in KICS patient in 
comparison to KS and non-KS cases 
	 39	
A= Before KICS was established, patient was only diagnosed for KS, B=After 
KICS diagnosis, C=. (A) KSHV DNA and (B) HIV RNA levels in plasma from KICS 
patient at different timepoints A, B, C and D and KS (n=12) and non-KS patients (n=6). 
(C) IL-6, (D) IL-10 and (E) IL-8 on patient plasma, measure by ELISA. For KICS, data 
represents the mean ± SD of n=3 independent experiments of each plasma sample. For 
KS and non-KS, each data point represents the mean of n=3 independent measurements, 
the mean ± SD was calculated of the entire group (KS n=12 and non-KS n=6). Principal 
component analysis of the 34 cytokine measured by luminex that characterizes (F) the 




Figure II. 3: Deep-sequencing analysis of KICS patient at different timepoints 
reveals no mutation of the virus over time and alignment to clade A 
(A) Distribution of reads that align to KSHV (NC009333) genome. Timepoint A 
in red (before KICS was established) and timepoint B in grey (after KICS was 
diagnosed). Phylogenetic trees demonstrating alignment of generated consensus 
sequences for KSHV isolated from patient plasma, in comparison to (B) established 





CHAPTER III: TARGETING MTOR WITH MLN0128 OVERCOMES 
RAPAMYCIN AND CHEMORESISTANT PRIMARY EFFUSION LYMPHOMA1 
 
Importance 
Primary effusion lymphoma (PEL) is an aggressive and incurable malignancy, 
which is usually characterized by lymphomatous effusions in body cavities without tumor 
masses. PEL has no established treatment and a poor prognosis with a median survival 
time shorter than six months. PEL usually develops in the context of immunosuppression, 
such as HIV infection or post-organ transplantation. The optimal treatment for PEL has 
not been established, as PEL is generally resistant to traditional chemotherapy.  The 
molecular basis for PEL are still unknown; however, PEL displays a constitutively active 
mammalian target of Rapamycin (mTOR) pathway, which is critical for metabolic and 
cell survival mechanisms. Therefore, the evaluation of novel agents targeting the mTOR 
pathway could be clinically relevant for the treatment of PEL. 
Introduction 
Primary effusion lymphoma (PEL) is a non-Hodgkin B-cell lymphoma that is associated 
with infection by Kaposi sarcoma-associated herpesvirus (KSHV) (Cesarman, Chang et 






commonly in the pleural, pericardial and peritoneal cavities. This lymphoma generally 
develops in the context of immunosuppression, such as during HIV infection or organ 
transplantation (Jones, Ballestas et al. 1998). Currently, PEL is treated with a 
chemotherapeutic regimen containing cyclophosphamide, doxorubicin, vincristine and 
prednisolone (CHOP). Resistance develops rapidly with a median survival time of 6.2 
months (Komanduri, Luce et al. 1996, Boulanger, Gerard et al. 2005). Hence, there exists 
an urgent need to develop novel and targeted therapies for PEL. 
PEL are addicted to the mammalian Target of Rapamycin (mTOR) signaling 
pathway. All PEL tested display constitutively active mTOR (Sin, Roy et al. 2007, Bhatt, 
Bhende et al. 2010). The mTOR pathway controls cell growth, metabolism, proliferation, 
angiogenesis, and survival (reviewed in (Saxton and Sabatini 2017)) and is activated in a 
large number of cancers. In non-viral cancers, this is often due to activating mutations 
upstream of mTOR and/or loss of tumor suppressors such as the phosphatase and tensin 
homolog (PTEN). In PEL, PTEN is intact but inactivated by phosphorylation (Roy and 
Dittmer 2011). Several viral proteins, such as ORFK1 (K1) (Tomlinson and Damania 
2004), ORFK2 (vIL6) (Tomlinson and Damania 2004), ORF45 (Kuang, Tang et al. 2008) 
and ORF74 (vGPCR) (Sodhi, Montaner et al. 2004, Sodhi, Chaisuparat et al. 2006, 
Morris, Punjabi et al. 2008) induce the mTOR pathway in PEL as well as in Kaposi’s 
sarcoma (KS).  
The mTOR kinase functions in two structurally and functionally distinct 
complexes designated as mTOR complex 1 (mTORC1) (Hara, Maruki et al. 2002, Kim, 
Sarbassov et al. 2002) and complex 2 (mTORC2) (Jacinto, Loewith et al. 2004, 
Sarbassov, Ali et al. 2004).  mTORC1 targets p70-S6 kinase 1 (p70S6K1) and eukaryotic 
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translation initiation factor 4E-binding protein 1 (4EBP1). mTORC1 phosphorylates 
p70S6K1 at Thr389, which in turn phosphorylates ribosomal protein S6 (RPS6) thereby 
promoting protein synthesis (Magnuson, Ekim et al. 2012). mTORC1 also 
phosphorylates 4EBP1 at multiple sites, which causes dissociation from eukaryotic 
translation initiation factor 4E (eIF4E), promoting cap-dependent translation. mTORC2 
phosphorylates Akt (also known as protein kinase B) at Ser473. Akt in turn activates 
mTORC1 through a positive feedback loop (Sarbassov, Guertin et al. 2005, Guertin, 
Stevens et al. 2006) as well as additional pro-survival proteins. Another mTORC2 target 
is SGK1. AKT and SGK1 are members of the AGC family of kinases. They have both 
distinct and overlapping roles (Zhang, Cui et al. 2005, Garcia-Martinez and Alessi 2008). 
mTORC2 phosphorylates SGK1 at Ser422, as well as one of SGK1 physiological targets, 
N-myc downstream-regulated gene 1 (NDRG1) (Murray, Campbell et al. 2004). 
Phosphorylation of these proteins represents the best understood biomarker of mTORC 
activity. 
Rapamycin and its analogs (rapalogs) are allosteric inhibitors of mTORC1. We 
and others previously reported that rapamycin had preclinical activity against in PEL as 
well as clinical efficacy against KS (Stallone, Schena et al. 2005, Sodhi, Chaisuparat et 
al. 2006, Sin, Roy et al. 2007, Krown, Roy et al. 2012, Roy, Sin et al. 2013). Switching 
from Cyclosporine A to rapamycin has become the standard of care for transplant-
associated KS. Unfortunately, rapamycin only arrests cells; it does not induce apoptosis 
and resistance develops readily (Gasperini and Tosato 2009). While rapamycin always 
inhibits p70S6K1 and RPS6, its effect on 4EBP1 is more variable (Choo, Yoon et al. 
2008, Feldman, Apsel et al. 2009, Thoreen and Sabatini 2009). Since rapamycin does not 
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target mTORC2, this may result in a compensatory activation of Akt and mTORC2, at 
least until enough mTOR kinase is trapped in inactive Rapamycin-FKBP-mTORC1 
complexes to start depleting mTORC2 (O'Reilly, Rojo et al. 2006). These limitations 
triggered the development of second-generation, ATP-competitive inhibitors, which 
target both mTORC1 and mTORC2.  
This is the first study of an ATP-competitive inhibitor in PEL. We focused on 
MLN0128 (INK128, Sapanisertib), rather than other ATP-competitive inhibitors, because 
MLN0128 is oral bioavailable and farthest along in clinical development (Ghobrial, 
Siegel et al. 2016, Kunati and Xu 2016, Burris, Kurkjian et al. 2017). MLN0128 inhibited 
both mTORC1 and mTORC2 in PEL at a nanomolar IC50 and induced rapid apoptosis 
rather than G1 arrest. MLN0128 was efficacious against doxorubicin-resistant PEL, such 
as the BCP-1 isolate, as well as rapamycin-resistant PEL. Furthermore, MLN0128 had 
reproducible efficacy in PEL xenograft models.  Based on these studies the clinical 
evaluation of MLN0128 in PEL and KS seems warranted. 
Methods 
Compounds and cell culture. MLN0128 and Rapamycin were purchased from 
Selleckchem. Compounds were dissolved in DMSO (Sigma-Aldrich), aliquoted and 
stored at -80°C. Cell lines were cultured in RPMI1640 supplemented with 100U/mL 
penicillin-streptomycin (Thermo Fisher), 2 mM L-glutamine (Thermo Fisher) and 10% 
FBS (Sigma-Aldrich), maintained at 37°C in 5% CO2 and passaged for no more than 3 
months. BC-1, BCBL-1, BC-3 and BCP-1 were obtained from ATCC. BCBL-1TrexRTA 
were a gift of J. Jung (Nakamura, Lu et al. 2003). RedFectTM (Perkin Elmer) was used to 
confer continuous red-luciferase expression (BCBL-1TrexRTA-luc) and cells maintained 
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in Hygromycin B (20 µg/mL) and Puromycin (1.25 µg/mL). Cell lines were authenticated 
by NextGen-based HLA and STR typing (https://www.med.unc.edu/vironomics) and free 
of mycoplasma Mycoalert Mycoplasma Test Kit (Lonza).  
Cell proliferation and cell viability. Cells were cultured at indicated 
concentration of inhibitor and counted in octuplicates using trypan blue (Sigma). Cell 
viability was determined at 48 hours by CellTiter-Glo® Assay (Promega) as per 
manufacturer instructions. Luminescence was measured at 560 nm using FLUOstar 
Optima (BMG Lab Tech). IC50s were calculated using R. 
Colony Formation. Cells were plated in triplicates in 10% FBS Complete RPMI 
media with 1% methylcellulose containing the indicated concentration of inhibitor.  
Colonies were counted after 2 weeks using a Leica MZ 6 microscope. 
Apoptosis and cell cycle. Cell were treated the indicated concentration of 
inhibitor and incubated for 24, 48, 72, and 96 h. For apoptosis assay, cells were washed 
in ice-cold PBS and re-suspended in binding buffer containing Annexin V and Propidium 
Iodide (Life Technologies). For cell cycle assay, cells were washed with cold PBS, fixed 
with cold 100% ethanol, treated with RNase A and stained with 10 µg/ml Propidium 
Iodide in PBS. 100,000 events were collected on MacsQuant VYB (Miltenyi Biotec) and 
analyzed using FlowJo v10.1 (Tree Star). 
Immunoblotting. Cells were treated with indicated concentration of inhibitors 
and lysed in RIPA buffer supplemented with protease inhibitor cocktail (Roche), 30 mM 
beta glycerol phosphate, 50mM sodium fluoride and 1mM sodium orthovanadate; 
incubated for 1 h on ice and centrifuged at 14,000 g for 5 minutes at 4°C. Protein 
concentration was determined by BCA assay and equal amounts of protein were loaded 
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onto 10% SDS-polyacrylamide gel, separated by electrophoresis and transferred to a 
PVDF membrane (Sigma-Aldrich). The following primary antibodies were used at 
1:1000 dilution: Phospho-S6 Ribosomal Protein Ser240/244 (#2215), S6 Ribosomal 
Protein 5G10 (#2217), Phospho-4E-BP1 Ser65 (#9451), 4E-BP1 (#9452), Phospho-AKT 
Ser473 D93 XP (#4060), AKT pan 11E7 (#4685), Phospho-NDGR1 Thr346 (#3217), 
NDRG1 D6C2 (#9408), Cleaved Caspase-3 Asp175 (#9664), Cleaved PARP Asp 214 
D64E10 XP (#5625) (Cell Signaling) and β -actin (A5441) (Sigma). Signal was detected 
with HRP-conjugated secondary antibodies (Vector Labs) and developed using ECL 
substrate (Pierce). Phosphorylated proteins were detected first, then membranes were 
stripped with One Minute Advance Western Blot Stripping Buffer (GM Biosciences) and 
probed for total protein. 
ELISA. IL-6 and IL-10 were quantify using ready-set-go kit (eBioscience) per 
manufacturer instructions. Plates were washed with plate washer ELx405 (Biotek). 
Absorbance was measured at 450 nm using spectrophotometer Infinite M200 PRO 
(Tecan).  
Kinome Scan. DiscoveRx 442 kinome-wide selectivity profiling was conducted 
by DiscoveRx Bioscience with KinomeScanTM Technology. 
Xenograft studies. 6-week-old female NSG mice (Jackson Laboratory) were 
injected IP with 1x105 cells. After 3 days, mice were randomized to a vehicle or 
treatment group, based on initial luminescent results before drugs injections. MLN0128 
and rapamycin was administered by IP or SC injections as indicated. The entire study 
group was euthanized, when the vehicle group body score dropped below 2 or >20% loss 
of body weight. Effusion volumes were collected from the peritoneal cavity and 
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measured. In mice that did not had any effusion to be collected, the cavity was washed 
with PBS to obtained PEL cells still present on the cavity. Effusions were diluted 1:3 
with cold PBS with 2% FBS, centrifuged at 300g for 5 min, supernatant and cell pellets 
were flash frozen and stored at -80. Every experiment has an n=5 for each treatment 
group, based on power calculations to record statistically significant (p≤0.05) alterations 
for individual measures. All mouse studies were performed by the UNC Lineberger 
Animal Studies Core Facility, the investigator was not present during group 
randomization or outcome assessment of bioluminescent measurements and fluid 
collection. 
Bioluminescent Imaging. Bioluminescent imaging was performed using the 
Xenogen IVIS-Lumina System (Caliper Life Sciences). Mice were anesthetized using 2% 
isoflurane and 100% oxygen at a flow rate of 2.5 l/min. Then 10µl/gram of a 15 mg/ml 
sterile D-Luciferin firefly substrate (Biosynth International Inc.) dissolved in PBS was 
administered by IP injection, and 15 minutes after substrate injection, the mice were 
imaged for up to 2 minutes.  Each image was saved for subsequent analysis. The images 
were analyzed with living image 4.2. The scales to the right of images in Figure 4D 
represent the photon emission from the tissue surfaces and are expressed as 
photons/second/centimeter squared/steradian (p/s/cm2/sr).  
PET-CT imaging. MicroPET and microCT images were acquired with an 
eXplore Vista small animal PET/CT scanner (GE Healthcare) with center resolution of 
1.2 mm and a 46-mm axial field of view.  Food was removed from mouse cages at least 
four hours before radiotracer injection. Mice were anesthetized in an induction chamber 
with a 3% isoflurane/oxygen mixture (v/v), then injected intravenously via tail vein 
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catheter with approximately 300µCi of [18F]FDG. The syringe and catheter were then 
removed and residue activity measured and subtracted from the total injected activity. 
After the injection, mice were allowed to recover from anesthesia and placed back in the 
cage to resume activity. Approximately 45 minutes after injection of the radiotracer mice 
were placed back in the induction chamber with 3% isoflurane, which was reduced to 
1.5% for maintenance of anesthesia before the animal was placed prone on the PET 
cradle, with legs secured to the side. A respiratory monitor (SA Instruments, Inc., Stony 
Brook, NY) was placed above the animal. Temperature was monitored with an infrared 
thermometer and maintained with a heat lamp. A CT scan of the animal’s abdominal 
region was then taken for attenuation correction and anatomical reference, with a tube 
current of 140µA and voltage of 40kVp. Sixty minutes after the injection of the 
radiotracer, a 20-minute static PET scan of the abdominal region was acquired. PET 
emission data were corrected for decay/dead time, and reconstructed with the Vista 
software using a 2D ordered subset expectation maximization (2D-OSEM) algorithm 
which corrects for random coincidences, scatter and attenuation, and calibrates the image 
to standardized uptake value (SUV). 
Drug resistance. Cell lines resistant to rapamycin (RR1, RR2, RR3) were 
generated by exposing the parental PEL cell line BCBL-1TrexRTA-Luc to an increasing 
dose of rapamycin (up to 1000 nM / 100x IC50) for 3 months. Clones were obtained by 
extracting and expanding a single colony from a colony formation assay. Clones were 
maintained at 100 nM of rapamycin. 
Exome sequencing and mutation calling analysis.  Total nucleic acid was 
extracted from 1x106 cells using MagNA Pure Compact Nucleic Acid Isolation Kit I 
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Large Volume Kit (Roche) and quantitated by Qubit 3.0 dsDNA HS Assay (Life 
Technologies). Barcoded exome sequencing libraries were prepared from 100 ng DNA 
with Ion AmpliSeq Exome RDY Library Preparation Kit (Life Technologies) using 
protocol MAN00009808 Rev: A.0. Libraries were quantitated by Qubit dsDNA HS 
Assay, sized with Agilent Bioanalyzer 2100 High Sensitivity DNA Assay (Agilent 
Technologies), and pooled to 80 pM final concentration. Templating and loading onto the 
Ion 540 Chip (Life Technologies) were automated on the Ion Chef (Life Technologies). 
Samples were sequenced on the Ion S5 System (Life Technologies). Base calling, quality 
filtering, and demultiplexing were performed on the Ion S5 (Life Technologies) with 
default parameters. Raw reads were trimmed to > 50 bp and mapped to the human 
genome (NCBI build hg38_2016) using CLC Genomics Workbench 9 (CLC bio). The 
CLC basic variant detection tool was used with parameters minimum average quality 
score = 19, minimum frequency = 90%, minimum coverage = 40. Only SNP calls with 
forward and reverse balance 0.25 < x < 0.75 were included in the analysis. 
RNASeq and Analysis. Total RNA was purified, polyA-enriched using Oligotex 
mRNA Mini Kits (Qiagen). Library preparation was performed according to Ion Total 
RNA-Seq Kit v2, whole transcriptome RNA protocol (ThermoFisher Scientific, 
Publication #MAN0010654 Revision B.0) with the following modifications: purification 
of fragmented RNA and cDNA was with 1.8x Agencourt RNAClean XP beads (Beckman 
Coulter, Inc.) (Ovation Universal RNA-Seq System User Guide, NuGEN), and an 
additional Agencourt AMPure XP 1.0x bead (Beckman Coulter, Inc.) cleanup of the 
finished library was performed. Libraries were quality-controlled and quantitated using 
2100 High Sensitivity DNA Assay (Agilent Technologies) and Qubit dsDNA HS Assay 
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(ThermoFisher Scientific). 50 pM of library was templated on the Ion Torrent Chef for 
200bp and sequenced on the Ion Torrent S5 using a 540 chip. Subsequent steps included 
quality control using bbduk version 37.25 (k=23 mink=11 ktrim=r hdist=1 
minlength=100 qtrim=rl trimq=20 ftl=10 ftr=600 maq=20 tpe tbo), mapping to reference 
genome (GRCh38, STAR aligner v2.5.3a, gencode v22 annotations), read counting on 
genes (summarizeOverlaps, mode: intersection-strict, singleEnd). Differential gene 
expression was calculated using DESeq2 working with a simple interaction term for the 
model: design = ~ Drug + Clone.Number. PCA, distance heatmaps, and other figures was 
generated in R using DESeq2 and ggplot2. Genes were considered differentially 
expressed by the Wald test, with an adjusted (Benjamini-Hochberg) p-value<0.05. Raw 
sequences are deposited under NCBI BioProject accession PRJNA414221. The complete 
code for analysis and gene list is deposited on bitbucket 
https://ddittmer@bitbucket.org/dittmerlab/rapamycin_mln0128_resistance_rnaseq.git 
Statistics. Results are reported as mean ± SD. All cellular experiments were 
repeated in at least three complete biological replicates. Unpaired 2-tailed t-test with 
Welch correction (do not assume equal SD) was used to statistically compare groups.  
Code Availability. For drug-response curves the public DRC package verison 3.0 
from R was used. The package is available at https://cran.r-
project.org/web/packages/drc/index.html. 
Study approval. Studies were approval by IACUC of the University of North 




MLN0128 inhibits PEL proliferation 
To compare MLN0128 and rapamycin, we tested several well-characterized PEL 
cell lines, such as BC-1 (KSHV and EBV positive) and BCBL-1 (KSHV positive, but 
EBV negative), across multiple experimental designs. (i) At 100 nM, MLN0128 inhibited 
PEL proliferation over time as measured by trypan blue exclusion assay (Figure 1A and 
B). (ii) MLN0128 abolished colony formation in soft agar. By contrast, rapamycin only 
reduced colony number to ~40% of the control for BCBL-1 (Figure 1C and D) and 
~20% of the control for BC-1 at the same concentration (Fig. S1 A and B). (iii) 
CellTiter-Glo® Assay (CTG) confirmed the previously reported IC50 values for 
rapamycin (Figure 1E, Fig. S1C). Of note, even at the highest concentration of 
rapamycin, there remained a resistant fraction of live cells, consistent with cell cycle 
arrest (Fig. S2). MLN0128 had a low nM IC50 values in this assay ranging from 9.71 to 
47.56 nM (Table 1). In contrast to rapamycin, no resistant fraction remained in 
MLN0128 treated cells (Figure 1F, Fig. S1D). When compared to two other rapalogs, 
temsirolimus and ridaforolimus, with improved solubility, MLN0128 still showed a more 
complete inhibition of PEL growth (Fig. S1E and F). All experiments were conducted at 
0.00002% of dimethyl sulfoxide (DMSO), which up to 0.1% final concentration had no 
effect on cell growth, data not shown. (iv) Levels of IL-6 and IL-10 were evaluated as 
these cytokines correlate with PEL proliferation and may function as autocrine growth 
factors (Drexler, Meyer et al. 1999, Carbone, Cesarman et al. 2010). As reported 
previously, IL-6 and IL-10 were significantly reduced upon treatment with rapamycin. 
Treatment with MLN0128 showed even greater reduction (Figure 2A and B). 
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Importantly, when the data is normalized to number of cells in each sample, the 
difference between IL-6 and IL-10 levels is not significant (data not shown), which 
confirms IL-6 and IL-10 as markers for PEL proliferation. Whether in addition of IL-10 
is more directly sensitive to mTORC status remains the subject of further studies. These 
results demonstrate that MLN0128 inhibits PEL proliferation in a manner on par or better 
than rapamycin, temsirolimus and ridaforolimus. 
 
MLN0128, but not rapamycin, induces apoptosis of PEL cell lines 
To test the hypothesis that MLN0128 induced cell death, (i) we used 
AnnexinV/PI flow cytometry to quantify apoptosis at 48 hrs. MLN0128 induced 
significantly higher levels of AnnexinV-positive cells than rapamycin in a dose 
dependent manner (Figure 2C). Representative flow cytometric plots are shown in Fig. 
S3. (ii) Apoptosis was confirmed by western blot for cleaved PARP and cleaved caspase 
3, which are established markers of apoptosis (Figure 2D).  MLN0128 induced 
accumulation of cleaved PARP and cleaved caspase 3, while rapamycin did not. In sum, 
MLN0128 induced apoptosis, whereas rapamycin did not. 
 
MLN0128 inhibits mTORC1 and mTORC2 signaling  
To examine if MLN0128 inhibited mTORC1 and mTORC2 in PEL cells, 
phosphorylated and total levels of validated downstream targets of mTORC1 (rpS6 and 
4EBP1) or mTORC2 (AKT and NGRD1) were measured. MLN0128 inhibited the 
phosphorylation of both mTORC1 targets, 4EBP1 (Ser65) and rpS6 (Ser240-244), as 
well as both mTORC2 targets, AKT (Ser473) and NDRG1 (Thr346) (Figure 3).  
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Rapamycin only partially inhibited mTORC1: phosphorylation of rpS6 was 
inhibited; yet 4EBP1 remained phosphorylated. As expected, rapamycin did not inhibit 
mTORC2. MLN0128 prevented feedback activation of AKT, while rapamycin led to the 
transient phosphorylation of AKT at Ser473 at 3 hours. To confirm the specificity, we 
subjected MLN0128 to a high throughput assay against 442 purified kinases (Table S1) 
(Liu, Kirubakaran et al. 2012). MLN0128 was specific for mTOR at 25 nM, which was 
similar to the IC50 for PEL (Figure S4A) (Yang, Rudge et al. 2013). At 10,000 nM 
MLN0128 showed a somewhat broader inhibition profile, similar to other mTOR/PI3K 
ATP-competitive inhibitors, such as WYE354, pp242, NVP-BEZ235 and Torin1 (Fig. 
S4); however, this concentration is ~1,000x higher than used here for PEL. With PEL 
being among the most mTOR addicted lymphomas the low IC50 for MLN0128 is 
consistent with primary inhibition of only mTOR kinase. These results establish that 
MLN0128 inhibits mTORC1 and mTORC2 activity without feedback activation of AKT.  
 
MLN0128 inhibit PEL growth in vivo 
To determine in vivo efficacy, we used an established xenograft model for PEL 
(Sin, Roy et al. 2007) augmented by live imaging. Unlike most other lymphomas PEL 
grow as effusions in patients. Hence, an IP model mimics the clinical representation. 
MLN0128 reduced PEL progression of BCBL-1 and BCBL-1TrexRTA-luc cells, as 
measured by effusion volume (Figure 4A) and IL-6 levels (Figure 4B). There was no 
significant difference between MLN0128 and rapamycin treatment (Figure 4A).  
To study this further, mice that no longer had overt effusions at the end of the 
observation period, the cavity was washed with PBS to collect any cells that may still be 
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present on the cavity. Live cells were quantified and showed a significant difference 
between mice treated with rapamycin and MLN0128 (Figure 4C). Weekly 
bioluminescence measurements showed a significant decrease of region of interest (ROI) 
luminescence with treatment (Figure 4D, E, Fig. S5A and B). To confirm these results, 
PET-CT was performed. This showed a significant decrease in tumor metabolism 
between the treated and vehicle group normalized to pre-treatment conditions (Figure 4F, 
Fig. S5C-E, Movie S1 and S2). To verify that the effusion contained PEL cells rather 
than mouse cells, we performed Giemsa stain that showed cells within the effusion had 
PEL-like features such as a prominent pleomorphic nucleoli and increased size compared 
to mouse cells (Fig. S5F-H). MLN0128 did not cause mortality or evident toxicity, 
demonstrated by constant body weight (Fig. S6); the treated mice remained active 
throughout the experiment. This demonstrates that MLN0128 inhibits PEL in vivo. 
 
MLN0128 induces apoptosis in rapamycin resistant PEL 
To test the hypothesis that MLN0128 was active against rapamycin-resistant (RR) 
PEL, we generated RR PEL, by culturing BCBL-1TrexRTA-Luc in increasing 
concentrations of rapamycin for 3 months followed by colony formation assay and single 
colony isolation. MLN0128 did not yield any colonies under the same schedule. Each of 
three RR clones exhibited a 6-fold increase in rapamycinIC50 compared to parental cells 
(Figure 5A and B). The surviving fraction increased ~20% to ~60% in the RR compared 
to the parental clone. Even though, MLN0128IC50 had 2-fold increase between the parental 
and RR clones, MLN0128 was still effective at decreasing PEL viability to 0% in all RR 
clones (Figure 5C and D).  
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Additionally, MLN0128 induced apoptosis in both RR and parental clones to a 
similar degree (Figure 5E). Exome sequencing of both parental and RR clones did not 
uncover mutations in mTOR, FKBP1 or other known genes in the mTOR pathway. To 
test whether transcriptional changes correlated with rapamycin resistance, we performed 
RNAseq. Principal component analysis uncovered significant and consistent differences 
between three parental and three RR clones (Fig. S7A). The most consistent change was 
the upregulation of IL-10 in the RR clones (Figure 5G, Fig. S7B). This was also reflected 
at the protein level since the RR clones exhibited a ~100-fold increase of secreted IL-10 
by comparison to the parental clones (Figure 5F). In sum, MLN0128 is efficacious even 
against RR PEL. 
Discussion 
PEL is a particularly aggressive type of post-germinal center B cell lymphoma, 
which is caused by KSHV, and which manifests as liquid effusions in body cavities. 
Prognosis is poor and resistance to conventional chemotherapy develops quickly. A 
defining feature of PEL is their dependence on PI3K/Akt/mTOR signaling, which seems 
to be driven by viral proteins rather than activating mutations in this pathway.  
Consequently, mTOR inhibitors such as rapamycin (Sin, Roy et al. 2007) and 
PI3K/mTOR inhibitors such as NVP-BEZ235 (Bhatt, Bhende et al. 2010) show 
preclinical efficacy. Unfortunately, NVP-BEZ235 was too toxic clinically (Carlo, Molina 
et al. 2016, Seront, Rottey et al. 2016), and rapamycin was cytostatic, rather than 
cytotoxic for PEL. While this suffices for rapamycin to control KS (Stallone, Schena et 
al. 2005, Krown, Roy et al. 2012) and to yield a clinical benefit in mantle cell lymphoma 
and renal cancer, it limits its use against a highly aggressive lymphoma such as PEL.  Of 
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note, the orally bioavailable rapamycin-derivative everolimus was clinically efficacious 
against advanced renal cell carcinoma patients, who progressed on pan-receptor tyrosine 
kinase inhibitors, such as sunitinib or sorafenib (Motzer, Escudier et al. 2008). This is 
consistent with mTOR being downstream of VEGF receptors, which are targeted by 
broad-spectrum receptor tyrosine kinase inhibitors, and which are known oncogenic 
drivers in PEL and KS. 
MLN0128 is an orally bioavailable, ATP-competitive inhibitor that targets 
mTORC1 and mTORC2. It showed promise in pre-clinical studies and has passed phase 
1 trials in multiple myeloma, non-Hodgkin’s lymphoma and Waldenström’s 
macroglobulinemia (Ghobrial, Siegel et al. 2016). This study established pre-clinical 
efficacy and mechanism of action for MLN0128 in PEL. MLN0128 had an IC50 of 10 – 
50 nM across multiple PEL cell lines (Table 1). This effective concentration is in range of 
currently approved cytotoxic agents for PEL (e.g. doxorubicin) as well as 
rapamycin/everolimus. While there are many targeted agents under consideration against 
KSHV-associated cancers, the only ones that demonstrated some clinical efficacy in KS 
had similar low nM IC50 in the PEL culture system. In the absence of a KS-tumor model, 
inhibiting PEL growth in culture and in xenografted mice represents the most stringent 
preclinical model for testing novel agents. 
 
Importantly, the action of MLN0128 was effective against a doxorubicin-resistant 
PEL cell line, BCP-1, therefore MLN0128 effectiveness was independent of p53 
mutation status in PEL (Petre, Sin et al. 2007). MLN0128 induced apoptosis, whereas 
rapamycin and its analogs only induced cell cycle arrest (Figure 2).  MLN0128 
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effectively inhibited mTORC1 and mTORC2 activity, while rapamycin caused a transient 
increase in Akt S473 phosphorylation, due to a feedback loop, indicating the presence of 
active mTORC2 (O'Reilly, Rojo et al. 2006)(Figure 3). There are various models that 
may explain the greater efficacy of MLN0128. Most likely, the dual inactivation of both 
mTORC1 and mTORC2 by MLN0128 might explain its greater effect on PEL as 
compared to rapamycin. This would also disrupt the compensatory upregulation of 
mTORC2 in response to mTORC1 inhibition as observed in solid tumors. Another 
explanation could be that the allosteric inhibitor rapamycin only inhibited some of the 
downstream pathways of mTORC1, whereas the ATP-competitive mTORC inhibitors 
tend to have a far broader effect on mTORC1 substrates (Feldman, Apsel et al. 2009). A 
third possibility could involve differential intracellular accumulation and pharmacology 
between rapamycin-derivatives and MLN0128. Lastly, rapamycin has been shown to 
inhibit KSHV reactivation, specifically RTA function (Nichols, Adang et al. 2011). We 
have not tested it, but presumably MLN0128 would do so as well and more completely. 
This in turn may down-regulate RTA-dependent oncoproteins of KSHV such as vGPCR 
(Sodhi, Montaner et al. 2004, Sodhi, Chaisuparat et al. 2006) or the viral protein kinase 
orf36, which is a functional homology of p70S6K (Bhatt, Wong et al. 2016). As PEL 
(and KS) are extraordinarily sensitive to mTORC inhibitors, the detailed study of these 
compounds in PEL may yield further mechanistic insights into their mechanism of action. 
 
MLN0128 was active in vivo at 1 mg/kg/day (Figure 4) and showed no toxicity. 
As previously noted, PEL develops resistance to rapamycin overtime. In culture, we were 
able to shift the IC50 for rapamycin by 100-fold within 3 months, while under the same 
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condition resistance to MLN0128 only changed 2-fold. The differential effect in PEL 
may be explained by the cytostatic activity of rapamycin, which gives PEL the chance to 
develop resistance. On the other hand, MLN0128 induces rapid apoptosis and therefore 
makes the development of resistance more difficult. Of note, we did not recover any 
previously described mutations in the RR clones, such as mutations in FKBP1. Our 
screen was limited as we only sequenced a few resistant isolates. At the same time, all the 
RR clones tested had an upregulation of IL-10 at transcriptional and protein level. This 
was consistent with the rapid adaptation in culture, rather than selection for resistance 
mutants. It may elucidate a mechanism of rapamycin resistance analogous to the role IL-7 
plays in mediating resistance to rapamycin in preclinical models B cell leukemia (Brown, 
Fang et al. 2003).  Importantly, MLN0128 was equally active against RR PEL as RR 
sensitive PEL (Figure 5). In total these studies establish the mechanism of action for 
MLN0128 in this lymphoma and suggests that clinical studies of MLN0128 in PEL and 




Table III. 1: MLN0128 IC-50 values for a panel of 5 PEL cell lines (n = 3) 
 
PEL Cell Line IC-50 (nM) 
 
BC-1 16.20 ± 4.94 
BCBL-1 37.43 ± 13.13 
BC-3 47.56 ± 7.48 
BCP-1 9.71 ± 0.76 




Figure III. 4: MLN0128 inhibits PEL proliferation 
 (A) BC-1 and (B-D) BCLB-1 cells were incubated with 100 nM of rapamycin or 
MLN0128, and inhibition of cell proliferation was assessed by (A, B) trypan blue 
exclusion assay at the indicated times or (C-D) colony formation assay after 2 weeks. 
Data represents the mean ± SD of n=3 independent experiments (Unpaired 2-tailed t-test, 
*p < 0.05, **p < 0.01 rapamycin vs. MLN0128 group). BCBL-1 cells were treated with 
increasing concentrations of (E) rapamycin or (F) MLN0128 for 48 hours, cell viability 
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was measured by CellTiter-Glo® Luminescent Cell Viability Assay. Dose-response 
curves were generated as a % of the vehicle (100%) and no cells control (0%) in R. Each 





Figure III. 5: MLN0128 induces PEL apoptosis 
 (A-B) BC-1 cells were treated with 100 nM of rapamycin or MLN0128 for the 
indicated times, (A) IL-6 and (B) IL-10 (PEL markers) on the supernatant were measured 
by ELISA. Data represents the mean ± SD of n=3 independent experiments (Unpaired 2-
tailed t-test, *p < 0.05, **p < 0.01, ***p<0.001 control vs. rapamycin or MLN0128 
group). BC-1 and BCBL-1 cells were treated with the indicated concentration of 
rapamycin and MLN0128 for 48 hours; cell apoptosis was measured by (C) Annexin V 
FACS, percentages indicate Annexin V-positive cells (apoptotic) normalized to control 
and (D) expression of cleaved PARP, cleaved caspase 3 and total S6 as loading control. 
Data represents the mean ± SD of n=3 independent experiments (Unpaired 2-tailed t-test, 
*p < 0.05, **p < 0.01, ***p<0.001 rapamycin vs. MLN0128 group). Western blots were 
repeated three times with similar results. 
	 63	
 
Figure III. 6: MLN0128 blocks both mTORC1 and mTORC2 in PEL 
BCBL-1 cells were treated with 100 nM of rapamycin or MLN0128 for 0 to 48 
hours, regular and phospho levels of S6, 4EBP1, AKT and NDGR1 were measured by 
western blot. β-actin was used as a loading control for whole cell extracts. Western blots 





Figure III. 7: MLN0128 inhibits PEL growth in xenograft models 
PEL xenograft models were treated with vehicle (n=25 total), rapamycin (n=5 
total) or MLN0128 (n=25 total) at the indicated concentration by IP or SC injections 
following a M-F dosing schedule for 4 weeks for BCBL-1TrexRTA-Luc or 8 weeks for 
BCBL-1 studies. Every experiment a-e had n=5 for each treatment group. MLN0128 
treated mice remained active and displayed no toxicity signs such as weight loss. (A) 
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Effusions were harvested and quantified at the end of the study and (B) IL-6 levels were 
measured by ELISA (Unpaired 2-tailed t-test, *p < 0.05, **p < 0.01, ***p<0.001 vehicle 
(n=5) vs. MLN0128 (n=5) group or vehicle (n=5) vs. rapamycin (n=5) per experiment a-
e). (C) PEL cell quantification of PBS cavity wash from mice with no effusion from 
experiment c (Unpaired 2-tailed t-test, *p < 0.05, **p < 0.01, ***p<0.001 MLN0128 
(n=5) vs. rapamycin (n=5) group). (D) Representative bioluminescent quantification of 
BCBL-1TrexRTA-Luc studies. (E) Representative image of bioluminescence imaging of 





Figure III. 8: MLN0128 induces apoptosis of rapamycin resistant clones 
 (A, C) Parental and (B, D) rapamycin resistant clones were treated with 
increasing concentrations of (A-B) rapamycin or (C, D) MLN0128 for 48 hours, cell 
viability was measured by CellTiter-Glo® Luminescent Cell Viability Assay. Dose-
response curves were generated as a % of the vehicle (100%) and no cells control (0%) in 
R. The IC50 and 95% confidence interval for rapamycin treatment of parental clone (A): 
1. IC50 = 0.09 ± 0.04 nM; 2. IC50 = 0.10 ± 0.03 nM; 3. IC50 = 0.08 ± 0.02 nM and 
rapamycin resistant clone (B): 1. IC50 = 0.68 ± 0.75 nM; 2. IC50 = 0.31 ± 0.24 nM; 3. IC50 
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= 0.69 ± 0.88 nM. MLN0128 treatment of parental clone (C): 1. IC50 = 14.65 ± 3.10 nM; 
2. IC50 = 15.09 ± 2.80 nM; 3. IC50 = 16.46 ± 5.25 nM and rapamycin resistant clones (D): 
1. IC50 = 35.70 ± 5.50 nM; 2. IC50 = 45.21 ± 8.90 nM; 3. IC50 = 38.39 ± 7.82 nM. Data 
represents the mean of n=4 independent wells. (E) Parental and rapamycin resistant 
clones were treated with 100 nM of rapamycin or MLN0128 for 48 hours; cell apoptosis 
was measure by Annexin V FACS, percentages indicate Annexin V-positive cells 
(apoptotic) normalized to control. (F) Levels of IL-10 was measured by ELISA in 
parental and RR clones after 24 or 48 hours of seeding time. Data represents the mean ± 
SD of n=3 independent clones (Unpaired 2-tailed t-test, *p < 0.05, **p < 0.01, 
***p<0.001 rapamycin vs. MLN0128 group). (G) RNA profile of parental and rapamycin 







Figure III. S 1: MLN0128 inhibits PEL proliferation (BC-1) 
 (A, B) BC-1 cells were incubated with 100 nM of rapamycin or MLN0128, 
inhibition of cell proliferation was assessed by colony formation assay after 2 weeks. 
Data represents the mean ± SD of n=3 independent experiments (Student t-test, *p < 
0.05, **p < 0.01 rapamycin vs. MLN0128 group). BC-1 cells were treated with 
increasing concentrations of (C) rapamycin or (D) MLN0128 for 48 hours, cell viability 
was measured by CellTiter-Glo® Luminescent Cell Viability Assay. (E) BC-1 and (F) 
BCBL-1 cells were treated with increasing concentrations of MLN0128 (MLN), 
rapamycin (rapa), everolimus (evero), temsirolimus (tem), ridaforolimus (rida) and 
tacrolimus (tacro) for 48 hours, cell viability was measured by CellTiter-Glo® 
Luminescent Cell Viability Assay. Dose-response curves were generated as a % of the no 
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Figure III. S 2: Flow cytometry histograms 
 (A) BC-1 and (B) BCBL-1 cells were treated with 100 nM of rapamycin and 
MLN0128 for 48 hrs. Cells were stained with propidium iodide and analyzed by FACS 
and FlowJo with the tool of cell cycle distribution. Representative FACS analysis in 
Flowjo for cell cycle distribution for BC-1 (C-E) and BCBL-1 (F-H), plots are live-gated. 
Data represents the mean ± SD of n=3 independent experiments (Student t-test, *p < 





Figure III. S 3: Gating strategy for delineating viable, early apoptotic, late apoptotic 
and necrotic cells. 
Representative FACS analysis in FlowJo from Annexin V/PI assay. (A-C) BC-1 
and (D-F) BCBL-1 cells were treated with 100 nM of rapamycin or MLN0128 as 
indicated and incubated for 48 hrs. In each panel, the lower left quadrant indicates viable 
cells (annexin negative, PI negative, Q4), lower right indicates early apoptotic cells 
(annexin positive, PI negative, Q3), the upper right quadrant indicates late apoptotic cells 
(annexin positive, PI positive, Q2) and the upper left quadrant indicates necrotic cells 





Figure III. S 4: Kinome trees of mTOR inhibitors 
Kinome tree depiction of (A) MLN0128 and (B) other ATP-competitive inhibitors 
targets in protein kinases, generated using DiscovRx TREEspot Version 4. The screen for 
(A) MLN0128 was performed at 25, 250, 1,000 and 10,000 nM., while the screen for (B) 
WYE354, pp242, BEZ235 and Torin 1 was performed at 10,000 nM. Data for WYE354, 
pp242 and Torin 1, were obtained from (Liu, Kirubakaran et al. 2012). Only kinases with 
a S score of <5% relative to DMSO control are shown. S score indicated the relative 
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selectivity properties of the drugs with smaller S values signifying a more selective 
compound. The sizes of the red circle are proportional to the strength of the binding; 






Figure III. S 5: Tumor burden in mice and giemsa stains 
(A-B) In vivo bioluminescent imaging, mice were injected with BCBL-
1TrexRTA-Luc, PEL cells expressing luciferase. Mice were anesthetized and 
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luminescence was imaged after IP injection with d-luciferin. Mice were imaged once a 
week, starting 3 days after the injection of PEL cells. (C-E) Quantitative PET-CT 
measurements of FDG uptake by PEL tumors. BCBL-1 cells were intraperitoneally 
injected and mice were treated from M-F with MLN0128 1 mg/kg (n=5) or vehicle (n=5). 
Histogram of the standard uptake value (SUV) within the intraperitoneal region of 
interest (ROI) (60 bins, from 0-3 SUV) for PET-CT imaging (A) 1 week before cell 
injection to obtain background measurement (n=10) and (B) 6 weeks after MLN0128 
treatment (n=5) or vehicle (n=5). (C) Statistical analysis of vehicle (n=5) and MLN0128 
(n=5) group based on gut ROI SUV per muscle ratio normalized to control. Data 
represents the mean ± SD of n=5 animals per experimental group (Student t-test, *p < 
0.05, **p < 0.01, ***p<0.001 MLN0128 vs. vehicle group). (F-H) Representative 
Giemsa stain of peritoneal effusions from untreated mice. Effusion were spun into 
cytospin slides and stained with Giemsa solution. Mouse red blood cells are identified by 





Figure III. S 6: Effect of MLN0128 treatment on mice body weight 
Body weight of mice injected intraperitoneally with (A-C) BCBL-TrexRTA-Luc and (D-
E) BCBL1 treated with MLN0128 (1-3 mg/kg), rapamycin (3 mg/kg) or vehicle (20% 
DMSO). Changes in body weight were monitored through the course of each study. Data 
represents the mean ± SD of n=5 animals per experimental group.
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Figure III. S 7: PCA analysis and volcano plot of parental vs. rapamycin resistant 
clones 
(A) Principal component analysis (PCA) of rapamycin resistant clones (n=3) 
displayed as triangles and parental clones (=3) displayed as circles. Total 2-dimensional 
PCA mapping represent 87% of variance (PC1 = 67% and PC2 = 20%). (B) Volcano plot 
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displaying differential expressed genes between rapamycin resistant and parental clones. 
The y-axis corresponds to the mean expression value of log 10 (p-value), and the x-axis 
displays the log2 fold change value. The red dots represent the most significant (p < 1x10-
6) transcripts with differential expression between rapamycin resistant and parental 
clones. The grey dots represent the non-significant transcripts (p > 1x10-6). between 





CHAPTER IV: DISCUSSION AND CONCLUDING REMARKS 
 
My dissertation has focused on further elucidating the pathogenesis of KSHV-
associated inflammatory cytokine syndrome (KICS) (Chapter 2) and the treatment of 
primary effusion lymphoma (PEL) with MLN0128 (Chapter 3). Patients of both PEL and 
KICS have a poor prognosis and there is no standard-of-care treatment. Elucidating the 
processes which promote pathogenesis in these diseases will allow for the development 
of drugs or therapies that may be effective in treating these diseases. Further pre-clinical 
testing of the efficacy of the drugs is critical in helping move drugs forward into clinical 
studies. My work has highlighted (a) the differential pathogenesis between KICS and 
other KSHV causing diseases, and (b) the effectiveness of MLN0128 as treatment for 
PEL. My research was performed under the mentorship of Dr. Dirk Dittmer at UNC 
Chapel Hill. 
Kaposi’s sarcoma-associated herpesvirus (KSHV) is the causative agent of 
Kaposi’s sarcoma (KS) (Chang, Cesarman et al. 1994), PEL (Cesarman, Chang et al. 
1995), KSHV-associated multicentric Castleman disease (KSHV-MCD) (Soulier, Grollet 
et al. 1995) and KICS (Uldrick, Wang et al. 2010). My dissertation focuses only on PEL 
and KICS; however, its findings may have ramifications on other KSHV-associated 
diseases. PEL is an aggressive B-cell lymphoma usually characterized by effusions in the 
body cavities, such as in the pleural, pericardial and peritoneal cavities. Currently, 
patients of PEL are treated with cyclophosphamide, doxorubicin, vincristine and 
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prednisolone (CHOP), but have a short median survival time of 6.2 months after 
prognosis (Boulanger, Gerard et al. 2005). KICS is characterized by flares of KSHV 
reactivation and has a very poor prognosis (Polizzotto, Uldrick et al. 2016). KS is 
typically associated with elevated levels of IL-8 and VEGF (reviewed in (Mesri, 
Cesarman et al. 2010)). PEL is associated with elevated IL-6 and IL-10 levels, though in 
culture IL6-negative PEL cell lines have been described. The two main biomarkers of 
KICS are elevated systemic levels of IL-6 and IL-10. However, most molecular 
mechanisms of KICS pathogenesis are still unknown. 
My dissertation is divided in chapters; however, all projects focus on diseases 
caused by KSHV. Chapter 1 is a review on the different mechanisms KSHV and other 
herpesviruses employ to modulate the mammalian target of rapamycin (mTOR) pathway 
for their own advantage. mTOR is a master regulator of cellular pathways, including 
protein synthesis, apoptosis and autophagy. Therefore, viruses have developed different 
mechanisms to maintain an aberrant activation of mTOR to (i) promote protein synthesis 
and (ii) prevent cellular autophagy and death. Chapter 2 is a research project comparing 
disease biomarkers of a single KICS patient to other KSHV-associated diseases, and 
further examining KICS pathogenesis of a single patient over-time. KICS is a rare disease 
in the western world; therefore, obtaining different timepoints over the course of the 
disease is invaluable. Finally, Chapter 3 is a research project focusing on the comparison 
of rapamycin (an allosteric mTOR inhibitor) and MLN0128 (an ATP-competitive mTOR 
inhibitor) in the treatment for PEL. Several malignancies, such as PEL, have an aberrant 
activation of mTOR, making the mTOR pathway a good target for chemotherapeutic 
treatments. 
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In further detail, for Chapter 2 the samples were obtained from an HIV-positive 
45-year old male admitted at UNC. He was later diagnosed with KICS and treated with 
tocilizumab, an IL-6 receptor inhibitor. We obtained blood samples from four different 
time points, when: (A) The patient was diagnosed with KS, but had no official diagnosis 
of KICS, (B) The patient was diagnosed with KICS and had received the first dose of 
tocilizumab, (C) an hour after the patient received a second dose of tocilizumab and (D) 6 
days after the patient was treated with tocilizumab.  
The patient had an elevated KSHV viral load, which decreased more than a log-
fold after treatment with tocilizumab. The KS group had lower viral load in comparison 
to the KICS patient with a 3-log fold-difference between the lowest viral load measured 
in the KICS patient compared to the average viral load in the KS group (Figure II.2.A). 
Additionally, the KICS patient had an undetectable HIV viral load (Figure II.2.B). 
Unexpectedly, the patient did not exhibit elevated levels of IL-6. However, his IL-6 level 
increased dramatically after tocilizumab treatment (Figure II.2.). Tocilizumab is an IL-6 
receptor antibody that can be detected by ELISA, giving a false positive result. On the 
other hand, IL-10 had a 3-fold increase after the patient was officially diagnosed with 
KICS followed by a drastic decrease to almost undetectable levels after 6 days of 
tocilizumab treatment (Figure II.2.D). Additionally, we used Luminex-based multiplex 
assay to study a broader range of cytokines. Based on a principal component analysis, 
cytokine levels in the blood obtained at different time points from the KICS patient were 
highly divergent from the KS group (Figure II.2.G). The driver of this progression were 
IL-10 and IL-6. 
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Finally, we sequenced the complete KSHV genome isolated from KICS patient. 
Timepoints A and B were successfully sequenced with good coverage, as enough DNA 
was present in the sample (Figure II.3.A). We compared the KSHV-KICS consensus 
sequences obtained to KSHV reference sequence, and no mutation associated with a 
KSHV high replicative phenotype was identified. Both KSHV-KICS consensus 
sequences aligned to the K1 clade and were closely related to BAC16, JSC1 (cell line) 
and GK1B sequences (Figure II.3.B,C). 
Based on our findings we concluded that IL-6 might not be the main KICS 
biomarker, as this specific patient only presented elevated IL-6 after tocilizumab 
treatment. However, tocilizumab did succeeded in reducing IL-10 to undetectable levels. 
It would be interesting to test alternative therapies of KICS patient and use their cytokine 
levels as biomarkers for pathogenesis. 
Chapter 3 focuses on comparing MLN0128 and rapamycin as treatment for PEL. 
MLN0128 (also known as INK128 or sapanisertib) is an ATP-competitive inhibitor, 
capable of targeting both mTOR complex 1 (mTORC1) and mTOR complex 2 
(mTORC2). Thus, (i) it is more active against mTORC1, as it inhibits a larger range of 
substrates and (ii) is active against mTORC2, where it inhibits an additional set of non-
overlapping targets. MLN0128 has been successful in pre-clinical studies for the 
treatment of different malignancies. Currently, MLN0128 has passed clinical phase 1 
trials and is undergoing phase 2 trials for relapsed lymphoma and metastatic renal 
carcinoma. Rapamycin (sirolimus) is an allosteric inhibitor of mTOR, only capable of 
partial inhibition of mTORC1. It has previously been shown that rapamycin can 
effectively inhibit PEL proliferation and induce a cell cycle arrest at the G1/G0 phase. 
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However, rapamycin does not induce apoptosis, which limits its clinical efficacy as PEL 
can eventually develop resistance to rapamycin.  
We compared the effects MLN0128 and rapamycin had on PEL proliferation by 
using a (i) viability assay, (ii) colony formation assay and (iii) dose-response assay. 
MLN0128 was more effective at inhibiting PEL proliferation than rapamycin in all assays 
(Figure III. 1). Interestingly, the rapamycin dose-response curve did not reach a 0% 
viability even at the highest concentrations, which hints that rapamycin is not capable of 
inducing PEL apoptosis (Figure III.1.E). We further tested MLN0128 and rapamycin 
effect on apoptosis by (i) ELISA, (ii) annexin V flow cytometry and (iii) western blots. 
As expected MLN0128 was very effective at inducing apoptosis in PEL, while rapamycin 
only had a minimal effect (Figure III.2). Additionally, we studied the mechanism by 
which MLN0128 inhibited PEL growth by testing the activation state of established 
downstream targets of mTORC1 and mTORC2. MLN0128 was capable of inhibiting 
both mTORC1 (RPS6 and 4EBP1) and mTORC2 (AKT and NDRG1) targets (Figure 
III.3). On the other hand, rapamycin was only capable of inhibiting RPS6 
phosphorylation and not 4EBP1. Remarkably, both AKT and NDRG1 phosphorylation 
were unregulated after 3 hours of treatment due to a feedback activation of mTORC2 
(Figure III.3).  
Due to MLN0128 effectiveness in vitro, we wanted to further study MLN0128 
using a PEL xenograft mouse model. We monitored disease progression by measuring 
the (i) effusion volume, (ii) total number of live cells, and (iii) tumor burden by (a) 
bioluminescent imaging and (b) PET-CT scan. MLN0128 and rapamycin had comparable 
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effectiveness in inhibiting PEL growth (Figure III.4.D). However, MLN0128 had a 
significant lower number of live cells in the collected effusions (Figure III.4.C).  
PEL also rapidly developed resistance to rapamycin after treatment for 3 weeks; 
PEL did not develop resistance to MLN0128 under the same conditions We showed that 
rapamycin resistance was sustained by an upregulation of IL-10 rather than from a 
specific mutation in mTOR or FKBP1 (Figure III.F,G). Importantly, MLN0128 was still 
effective at inducing apoptosis of rapamycin-resistant PEL cells (Figure III.5.E). In short, 
MLN0128 was more effective at (i) inhibiting proliferation, (ii) inducing apoptosis and 
(iii) preventing drug resistance than rapamycin, in both cellular and mouse models of 
PEL. 
Based on our findings, we recommend MLN0128 for clinical trial for treatment of 
PEL. MLN0128 has already passed phase 1 clinical trials for other malignancies, which 
further supports its low toxicity in humans.  
As of further directions, we would like to improve the effectiveness of rapamycin 
as treatment for PEL. As showed in this chapter, rapamycin only has a cytostatic effect in 
PEL, which leads to development of resistance. However, rapamycin still has two main 
advantages, as it is FDA approved its commercial low cost, which makes rapamycin a 
more accessible drug for low-income countries. Therefore, it is still be meaningful to 
determine the best combination therapy for the treatment of PEL using rapamycin. To 
accomplish this we will use a sanger whole genome CRISPR arrayed screen. The arrayed 
screen contains a single guide RNA per well, and two guide RNAs targeting each gene on 
the screen. We will use real time glo (promega) a non-toxic cell viability assay and a 
robotic arm for all the liquid handlings. In short, we will use FKBP1 as our positive 
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control to determine which gene knockouts renders rapamycin resistance, and therefore 
define which drugs would be an effective combination therapy with rapamycin. 
Additionally, the arrayed screen will provide the first complete list of essential genes for 
PEL. 
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